Development and Initial Evaluation of a Psychosocial Intervention for Individuals Recovering from a First Episode of Non-affective Psychosis by Waldheter, Evan J.
DEVELOPMENT AND INITIAL EVALUATION OF A PSYCHOSOCIAL 
INTERVENTION FOR INDIVIDUALS RECOVERING FROM A FIRST EPISODE OF 
NON-AFFECTIVE PSYCHOSIS 
 
 
Evan J. Waldheter, M.A. 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Psychology (Clinical). 
 
 
 
Chapel Hill 
2007 
 
     
 
     
 
    Approved by: 
 
    David Penn, Ph.D. 
 
    Donald Baucom, Ph.D. 
 
    Marilyn Hartman, Ph.D. 
 
    Jennifer Snyder, Ph.D. 
 
    Diana Perkins, M.D., M.P.H. 
 
 
      
  
  
ii 
ABSTRACT 
 
EVAN J. WALDHETER: Development and initial evaluation of a psychosocial intervention 
for individuals recovering from a first episode of non-affective psychosis 
(Under the direction of David Penn, Ph.D.) 
 
 
Background: Despite the effectiveness of medication in reducing symptoms in first 
episode psychosis, persistent functional impairments are common, and are associated with 
increased risk for relapse and poor long-term prognosis.  Adjunctive psychosocial 
interventions are needed to address these functional impairments and to assist with illness 
self-management and psychological adjustment.  The Graduated Recovery Intervention 
Program (GRIP) is a novel cognitive-behavioral therapy program designed to facilitate 
functional recovery in people who have experienced an initial episode of psychotic illness.  
Methods: The treatment development process of GRIP, including treatment 
conceptualization, manual development, and pilot testing, is described.  Results: Preliminary 
data from an open feasibility trial of GRIP are presented.  Findings suggest clinical and 
psychosocial benefits associated with GRIP.  Qualitative feedback indicates that the 
treatment was well- received by clients and therapists.  The retention rate of 67%, however, 
was somewhat lower than expected.  Conclusions : Initial data on the efficacy of GRIP are 
encouraging, although the study design and small sample size preclude more robust 
conclusions at this time.  A randomized controlled trial of GRIP, currently in progress, is 
seeking to improve treatment retention based on client feedback from the open trial, and will 
generate more data on the efficacy and tolerability of this novel intervention. 
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CHAPTER 1 
INTRODUCTION 
 
 The psychotic disorders are the most severe and disabling of all mental illnesses.  The 
most common cause of psychosis is schizophrenia, which is categorized as a non-affective 
psychotic disorder in order to distinguish it from affective psychotic disorders, such as 
bipolar disorder or major depression with psychotic features (American Psychiatric 
Association, 1994).  Schizophrenia typically emerges in late adolescence or early adulthood, 
and is characterized by an array of distressing and impairing symptoms, including “positive 
symptoms” (i.e., hallucinations, delusions), “negative symptoms” (e.g., affective flattening, 
avolition, and alogia), disorganized thought, speech, and behavior, general cognitive 
impairments (e.g., attention, memory, executive functioning), and social/occupational 
dysfunction (American Psychiatric Association, 1994; Mueser & McGurk, 2004).   In the 
United States alone, schizophrenia currently afflicts more than two million people and has a 
lifetime prevalence of 1%, with 200,000 new cases diagnosed each year (Cornblatt, Green, & 
Walker, 1999; Torrey, 1995). 
 Individuals with schizophrenia progress through a series of phases, reflecting 
changing signs and symptoms as the illness progresses over time.  The “premorbid phase” 
represents the time period prior to onset of the illness, and there is compelling research 
documenting the presence of early cognitive, social, and motor impairments in many people 
that later develop schizophrenia (Lieberman, Perkins et al., 2001; Walker, Kestler, Bollini, & 
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Hochman, 2004).  This phase is particularly meaningful because the level of premorbid 
functioning is a strong predictor of treatment response and long-term outcome in people with 
schizophrenia and other psychotic disorders (Edwards, McGorry, Waddell, & Harrigan, 
1999; Huber, Gross, & Schüttler, 1975; Malla, Norman, Manchanda, Ahmed et al., 2002; 
Malla et al., 2004; Perkins et al., 2004).  The “prodromal phase” represents the period prior 
to the emergence of frank psychotic symptoms.  This stage of the illness is characterized by 
increasing cognitive dysfunction, affective disturbance, and behavioral changes (e.g., social 
isolation), as well as a deterioration in role functioning (i.e., performance at school or work).  
Depression is common during this phase, as are negative symptoms, restlessness, anxiety, 
and irritability.  Further, the individual may report unusual perceptual experiences and 
beliefs, and/or behave in an odd or eccentric manner (Häfner, Löffler, Maurer, Hambrecht, & 
an der Heiden, 1999; Yung & McGorry, 1996).  The duration of the prodromal phase varies 
widely; on average it lasts approximately two years, but it can range from several days to as 
long as five years in some individuals (Häfner et al., 1999; Lieberman, Perkins et al., 2001). 
 The emergence of florid psychotic symptoms (e.g., hallucinations, delusions) marks 
the beginning of the “active (or acute) phase.”  During this time, psychotic symptoms, 
disorganized thought processes, and behavioral disturbances are most severe, and acute 
hospitalization is often required to manage symptoms and ensure the safety of the individual 
and/or others (ORYGEN Youth Health, 2004).  Following remission of acute symptoms, 
individuals enter the “residual (or recovery) phase,” in which attenuated positive and/or 
negative symptoms may be present, and cognitive difficulties and/or social functioning 
deficits often persist (Edwards et al., 2002; Grant, Addington, Addington, & Konnert, 2001; 
Hill, Schuepbach, Herbener, Keshavan, & Sweeney, 2004; Mayerhoff et al., 1994).  This 
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phase can last for years, and its duration varies significantly among individuals.  The level of 
clinical stability during this phase is highly variable and relapse prevention is a key goal of 
treatment (EPPIC, 2001). 
 With respect to long-term course, psychotic disorders are generally associated with a 
broad heterogeneity in outcomes (Harrison et al., 2001).  Among all the psychotic disorders, 
schizophrenia appears to be the most pernicious.  Schizophrenia is, on average, associated 
with a worse long-term outcome than other major mental illnesses, including major affective 
disorders and severe personality disorders (McGlashan, 1988).  Harrison et al. (2001) state 
that schizophrenia is best seen developmentally as an episodic disorder, with a minority of 
individuals achieving complete recovery (i.e., no residual symptoms and/or functional 
deficits, no need for ongoing treatment).  Indeed, long-term follow-up studies reveal that 
schizophrenia tends to be a chronic and frequently debilitating disorder, with a large 
proportion of individuals experiencing multiple relapses and persistent social and 
occupational impairments over the course of their lifetime (Davidson & McGlashan, 1997; 
Harrison et al., 2001; Hegarty, Baldessarini, Tohen, Waternaux, & Oepen, 1994; McGlashan, 
1988; Svedberg, Mesterton, & Cullberg, 2001; Wiersma, Nienhuis, Slooff, & Giel, 1998).  In 
addition to symptomatic and functional impairments, schizophrenia is also associated with 
increased rates of suicide, infectious disease and other physical illnesses, substance abuse and 
dependence, homelessness and/or dangerous living conditions, victimization, and psychiatric 
comorbidities such as depression, anxiety, and post-traumatic stress disorder (PTSD) (e.g., 
Birchwood, 2003; Harrison et al., 2001; McGlashan, 1988; Mueser & McGurk, 2004; 
Mueser & Rosenberg, 2003; Wiersma et al., 1998). 
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 Schizophrenia has been included among the world’s top ten most disabling medical 
conditions (Murray & Lopez, 1996) and is therefore associated with high societal costs.  In 
the early 1990s, the total direct (e.g., hospitalizations, medication) and indirect (e.g., lost 
wages) costs of treating schizophrenia in the United States were estimated between $32.5 
billion and $65 billion (Knapp, Mangalore, & Simon, 2004; Wyatt, Henter, Leary, & Taylor, 
1995).  Healthcare analysts have estimated that the costs of treating schizophrenia are 
typically between 1.5-3% of a country’s total national healthcare expenditures (Knapp et al., 
2004).  Further, a significant proportion of the costs associated with schizophrenia can be 
attributed to the high rates of relapse and re-hospitalization (Kane, 1999; Knapp et al., 2004; 
Wasylenki, 1994; Weiden & Olfson, 1995).  Indeed, it is believed that at least 50% of the 
costs associated with treating schizophrenia could be saved through better relapse prevention 
efforts (Wasylenki, 1994). 
The Need for Early Intervention in Psychosis 
 In an effort to improve the long-term outcome for individuals with schizophrenia and 
related psychotic disorders, research over the last two decades has increasingly focused on 
early identification and intervention for psychosis (e.g., Birchwood, Todd, & Jackson, 1998; 
Falloon et al., 1998; Kirch, Keith, & Matthews, 1992; Lieberman & Fenton, 2000; Malla & 
Norman, 2002; McGlashan, 1998; McGlashan & Johannessen, 1996; McGorry, 1992; 
Stephenson, 2000; Wyatt & Henter, 2001).  An initial impetus for this movement was the 
recognition of several failures in the standard treatment of early psychosis, such as long 
delays in the provision of effective treatment, traumatic and demoralizing initial treatment 
experiences, minimal engagement of patients with the healthcare system, and poor continuity 
of care (Edwards & McGorry, 2002).  It was widely acknowledged that current methods of 
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treatment for individuals with recent-onset psychosis were inadequate and possibly even 
harmful, and there was increasing speculation that more effective intervention strategies 
tailored to this specific phase of the illness may result in decreased morbidity and mortality 
over the long-term (McGlashan & Johannessen, 1996).  This approach has been bolstered by 
several critical findings, which are described below. 
Association between Duration of Untreated Psychosis and Outcome 
 Most studies have found that the sooner that antipsychotic treatment is initiated after 
the emergence of active psychosis, the better the clinical outcome (see reviews by 
Lieberman, Perkins et al., 2001; Norman & Malla, 2001).  Indeed, most studies find that a 
shorter duration of untreated psychosis (DUP) is associated with shorter times to remission, 
higher rates of remission, and/or higher levels of remission (i.e., greater reduction in 
symptoms), even after controlling for other factors such as premorbid functioning, age of 
onset, or gender (Black et al., 2001; Harrigan, McGorry, & Krstev, 2003; Larsen, Moe, Vibe-
Hansen, & Johannessen, 2000; Lieberman, Perkins et al., 2001; Loebel et al., 1992; Malla, 
Norman, Manchanda, Ahmed et al., 2002; Norman & Malla, 2001; Perkins et al., 2004; 
Rabiner, Wegner, & Kane, 1986; Ücok, Polat, Genc, Cakir, & Turan, 2004; Wyatt & Henter, 
2001).  Further, this effect may be strongest in patients with a DUP of less than six months 
(Carbone, Harrigan, McGorry, Curry, & Elkins, 1999; Malla, Norman, Manchanda, Ahmed 
et al., 2002). 
 The evidence supporting a relationship between DUP and long-term outcome is more 
equivocal.  Several recent studies have reported a significant relationship between shorter 
DUP and better long-term outcome, in terms of both symptomatic and functional status 
(Altamura, Bassetti, Sassella, Salvadori, & Mundo, 2001; Bottlender et al., 2003; Meagher et 
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al., 2001; Wyatt, Damiani, & Henter, 1998; Wyatt & Henter, 2001).  Other researchers, 
however, have failed to find such an association (Barnes et al., 2000; Craig et al., 2000; Ho, 
Andreasen, Flaum, Nopoulos, & Miller, 2000; Lehtinen, Aaltonen, Koffert, Räkköläinen, & 
Syvälahti, 2000).  It should be noted that, even in studies detecting a significant relationship, 
DUP has only been found to explain a limited amount of variance with respect to long-term 
outcome (e.g., 15%; Meagher et al., 2001).  Thus, some researchers have attributed negative 
findings in this area to methodological factors such as small sample sizes and limited 
statistical power (Harrigan et al., 2003). 
 While more research is needed to clarify the relationship between DUP and long-term 
outcome, treatment delays currently represent a significant public health concern, as mean 
DUP tends to be one year or more (Judge, Perkins, Nieri, & Penn, 2005; Lieberman & 
Fenton, 2000).  In addition to potential clinical damage and accumulating morbidity, 
extended DUP is often associated with increased risks of self-harm, aggressive behavior, 
family distress, substance abuse, and victimization (McGorry, Krstev, & Harrigan, 2000).  
Thus, reducing delays in the provision of effective treatment for early psychosis has the 
potential for improving outcomes on many levels. 
The Critical Period Hypothesis 
 Most research on psychotic disorders has found that the greatest amount of clinical 
and psychosocial deterioration occurs within the first five years of the onset of the illness 
(Birchwood et al., 1998; Davidson & McGlashan, 1997; Gupta et al., 1997; Harrison et al., 
2001; Lieberman, Perkins et al., 2001; Lieberman et al., 1998; Madsen, Vorstrup, Rubin, 
Larsen, & Hemmingsen, 1999; McGlashan, 1988, 1998; McGlashan & Johannessen, 1996; 
Pelosi & Birchwood, 2003).  There is compelling evidence that much of this deterioration 
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takes place during the prodromal phase, before the emergence of active psychosis (e.g., 
Birchwood et al., 1998; Caspi et al., 2003; Häfner et al., 1999; McGorry et al., 2000; 
Rabinowitz, De Smedt, Harvey, & Davidson, 2002).  In addition, the active disease process 
appears to level off, or “plateau,” after about five years in most individuals (Davidson & 
McGlashan, 1997; Huber et al., 1975; McGlashan, 1988; McGlashan & Johannessen, 1996). 
 Indeed, in long-term follow-up studies of individuals with schizophrenia, early (i.e., 
two-year) outcome has been the best predictor of long-term (i.e., 15-year) outcome (Harrison 
et al., 2001).  These data, taken together with research on DUP, strongly suggest that 
pharmacological and psychosocial treatment delivered early in the course of psychosis is 
likely to have a stronger impact than comparable treatment delivered at later stages of the 
illness. 
Relapse in Early Psychosis and the Development of Treatment Resistance 
 There is a very high risk of relapse following resolution of the first acute episode of 
psychosis.  Across a variety of studies, relapse rates range from 15-50% within the first year 
after an initial episode (Birchwood et al., 1998; Gupta et al., 1997; Rabiner et al., 1986), 30-
70% within the first two years (Birchwood et al., 1998; Davidson & McGlashan, 1997; 
McGlashan & Johannessen, 1996), and up to 80-85% within the first five years (Kane, 1999; 
Robinson, Woerner, Alvir, Bilder et al., 1999; Shepherd, Watt, Falloon, & Smeeton, 1989; 
Wiersma et al., 1998).  In general, the risk of relapse in early psychosis is significantly higher 
following medication discontinuation (Bradford, Perkins, & Lieberman, 2003; Gitlin et al., 
2001). 
 Relapse can be extremely traumatic for an individual with respect to clinical and 
psychosocial trajectory, and can evoke feelings of hopelessness, despair, and lack of control 
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over one’s illness (Birchwood, 2003; Birchwood & Spencer, 2001; Leete, 1987).  In addition, 
there is evidence suggesting that treatment resistance may develop over time with each 
subsequent relapse (Lieberman et al., 1998; Shepherd et al., 1989; Stephenson, 2000; 
Wiersma et al., 1998).  Lieberman (1999) reports that only 10-15% of patients are treatment-
resistant at the onset of illness, but that 30-60% eventually become treatment-resistant over 
time.  The time to remission tends to increase with each subsequent relapse in many patients, 
as does the likelihood of incomplete recovery.   
 These findings are consistent with research reporting progressive neuroanatomical 
and neuropsychological changes in at least a subset of patients with schizophrenia beginning 
with the first episode (e.g., Ho et al., 2003; Lieberman, 1999; Lieberman, Chakos et al., 
2001; Lieberman et al., 1998; Madsen et al., 1999; Stephenson, 2000).  Most of this 
neurobiological deterioration appears to occur within the first five years following illness 
onset, consistent with clinical observations (Keshavan, 1999; Lieberman et al., 1998).  
Further, these progressive brain changes are most likely to be found in patients with a poor 
long-term outcome, characterized by persistent negative symptoms and significant functional 
impairments (Ho et al., 2003; Lieberman, Chakos et al., 2001).  Given these findings, some 
researchers have postulated that schizophrenia is, in part, a neurodegenerative disease, and 
that periods of untreated active psychosis may be neurotoxic, leading to progressive 
deterioration and reduced capacity to respond to treatment (Lieberman, 1999).   Other 
researchers have acknowledged the presence of significant neuroanatomical abnormalities 
and neuropsychological dysfunction as early as the first episode, but have not detected 
progressive, irreversible changes in most patients.  They have argued against a 
“neurodegenerative” explanation of schizophrenia, and in favor of a “neurodevelopmental” 
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explanation, which links the disease to early (pre- and perinatal) and/or late (peri-adolescent) 
abnormalities in brain development (Fannon et al., 2000; Ho et al., 2003; Hoff et al., 2000; 
Vita, Dieci, Giobbio, Tenconi, & Invernizzi, 1997; Weinberger & McClure, 2002).  There 
have been recent efforts to bring these models together, with proponents of such a unitary 
approach suggesting that the pathophysiology of schizophrenia may best be explained as a 
combination of both neurodevelopmental abnormalities as well as neurodegenerative 
processes in at least a subset of individuals (Keshavan, 1999; Lieberman, 1999; Pantelis et 
al., 2003). 
 Despite discrepant findings regarding underlying neurobiological processes, it is clear 
that sustained and targeted intervention in early psychosis is essential in order to facilitate 
recovery from the first episode, reduce the risk of relapse and re-hospitalization (and 
associa ted societal costs), minimize personal suffering/trauma and psychosocial 
deterioration, and maximize therapeutic engagement during this critical period in the course 
of the illness (Birchwood et al., 1998; Lieberman & Fenton, 2000; McGlashan & 
Johannessen, 1996; Stephenson, 2000). 
Pharmacotherapy and Phenomenology of First Episode Psychosis 
 Low doses of atypical antipsychotic medications have been suggested as first- line 
treatment for first episode psychosis, with recommended maintenance treatment for at least 
one to two years following remission of symptoms (Bradford et al., 2003; Falloon et al., 
1998; Lieberman et al., 2003; Lieberman et al., 1998; McGorry, Killacket, Elkins, Lambert, 
& Lambert, 2003; Remington, Kapur, & Zipursky, 1998; Sanger et al., 1999).  Indeed, most 
individuals experiencing their first episode of psychosis are typically quite responsive to 
treatment with antipsychotic medication (Lieberman et al., 1992; Lieberman et al., 1993; 
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Remington et al., 1998; Robinson, Woerner, Alvir, Geisler et al., 1999; Sheitman, Lee, 
Strauss, & Lieberman, 1997).  A reduction of psychotic symptoms has been reported in 50-
65% of individuals within the first three months of treatment (Power et al., 1998; Tohen et 
al., 2000), 65-75% within six months (Tohen et al., 2000; Whitehorn, Brown, Richard, Rui, 
& Kopala, 2002), and up to 96% within one year (Bradford et al., 2003; Lieberman et al., 
2003; Malla, Norman, Manchanda, Ahmed et al., 2002; Robinson, Woerner, Alvir, Geisler et 
al., 1999).  In addition, early and sustained treatment with atypical antipsychotics may offer 
neuroprotective effects, minimizing the potential for further clinical and/or psychosocial 
deterioration (Lieberman, Perkins et al., 2001; Lieberman et al., 2005; Stephenson, 2000; 
Wyatt, 1991). 
 Clearly, pharmacotherapy is the cornerstone of treatment in first episode psychosis; 
however, several issues temper the beneficial effects of medication.  First, individuals with 
first episode psychosis are highly sensitive to the effects of antipsychotic medication and are 
particularly likely to experience unpleasant side effects such as weight gain and 
extrapyramidal symptoms (Bradford et al., 2003; Remington et al., 1998; Sanger et al., 
1999).  For example, in a Canadian study of 118 first episode patients taking atypical 
antipsychotic medication for one year, a large proportion of patients experienced significant 
weight gain, particularly within the first six months following treatment initiation 
(Addington, Mansley, & Addington, 2003).  Indeed, 60% of this sample was rated as 
“overweight” by the end of the study, compared with 36% of the sample at baseline.  Further, 
this weight gain occurred despite the provision of psychoeducation about the risks of weight 
gain and encouragement to maintain a healthy lifestyle.  Side effects such as weight gain in 
young people experiencing early psychosis are more likely to lead to reduced self-esteem, 
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associated physical health complications (e.g., diabetes), and increased medication non-
adherence (Addington, Mansley et al., 2003). 
 Second, many individuals experiencing early psychosis are non-adherent with their 
prescribed medication regimen (Perkins, 1999; Verdoux et al., 2000).  In a study of 200 
individuals being treated for a first episode of psychosis, Coldham and colleagues (2002) 
found that, by one year following treatment initiation, almost 60% of individuals were either 
“non-adherent” or “inadequately adherent.”  Medication non-adherence was associated with 
the presence of more psychotic symptoms, lower quality of life, more substance use, poorer 
insight, and a greater number of relapses.  Indeed, medication non-adherence has been noted 
as one of the most significant predictors of relapse (Robinson, Woerner, Alvir, Bilder et al., 
1999).  For example, Gitlin and colleagues (2001) followed 53 clinically stable individuals 
recovering from early psychosis who agreed to have their medication discontinued.  By one 
year following the discontinuation of medication, 78% of the sample had relapsed (defined as 
significant exacerbation of symptoms or re-hospitalization), and by two years, 96% had 
experienced a relapse.  Based on findings such as these, it is widely agreed that medication 
non-adherence and factors predisposing individuals to be non-adherent (e.g., side effects, low 
insight/denial, lack of efficacy, stigma, cognitive difficulties, substance use, greater symptom 
severity, inadequate support or supervision) need to be key targets of treatment, especially in 
early psychosis (Addington, Mansley et al., 2003; Birchwood et al., 1998; Fenton, Blyler, & 
Heinssen, 1997; Gray, Wykes, & Gournay, 2002; Kane, 1999; McGorry, 1992; Robinson, 
Woerner, Alvir, Bilder et al., 1999). 
 Third, despite treatment with antipsychotic medications, many individuals experience 
persistent, treatment-resistant symptoms.  It has been estimated that up to 20% of individuals 
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being treated for their first episode of psychosis will experience persistent positive 
symptoms, such as hallucinations and delusions (Edwards et al., 2002; Edwards, Maude, 
McGorry, Harrigan, & Cocks, 1998).  In addition, many individuals (i.e., 50% or more) will 
experience residual negative symptoms following a first episode, and approximately 5-10% 
of individuals will experience primary, enduring negative symptoms beginning with the first 
episode (Lieberman et al., 1992; Mayerhoff et al., 1994).  Indeed, current pharmacological 
treatments are significantly more effective at treating the positive symptoms of psychosis, 
and are less effective at treating negative symptoms (Bradford et al., 2003; Gupta et al., 
1997; Ho, Nopoulos, Flaum, Arndt, & Andreasen, 1998).  This is particularly problematic 
because the presence of primary and enduring negative symptoms (i.e., the “deficit state”) 
has been associated with higher levels of overall psychopathology, greater impairments in 
social functioning, a lower quality of life, and a more pessimistic prognosis (Edwards et al., 
1999; Ho et al., 1998; Malla et al., 2004). 
 Fourth, a large number of individuals recovering from a first episode of psychosis 
abuse alcohol and drugs.  Approximately 20% of individuals with recent onset psychosis 
abuse illicit drugs and/or alcohol on average; this rate is about twice that of healthy control 
samples (Hambrecht & Häfner, 1996; Sorbara, Liraud, Assens, Abalan, & Verdoux, 2003).  
Alcohol and cannabis abuse are particularly problematic among young people with psychosis 
(Edwards, Hinton, Elkins, & Anthanasopoulos, 2003; Green et al., 2004).  Indeed, previous 
studies have documented cannabis abuse and/or dependence in up to 70% of individuals with 
first episode psychosis (e.g., Power et al., 1998).  Cannabis and other substance use in people 
with psychotic disorders is associated with higher levels of symptomatology, increased 
treatment non-adherence, poorer treatment response, and higher rates of relapse and re-
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hospitalization (Elkins, Hinton, & Edwards, 2004; Green et al., 2004; Linszen, Dingemans, 
& Lenior, 1994; Sorbara et al., 2003).  In general, substance use in psychosis can 
significantly increase an individual’s biological vulnerability to develop symptoms, and can 
directly interfere with the effects of antipsychotic medications (Bellack & DiClemente, 1999; 
Mueser & McGurk, 2004); thus, it should be viewed as a significant barrier to recovery 
(Spaniol, Wewiorski, Gagne, & Anthony, 2002). 
 Fifth, emotional dysfunction is common in first episode psychosis, and increases the 
risk for relapse (Birchwood, Spencer, & McGovern, 2000).  Following an initial episode of 
psychosis, over 50% of individuals report significant depression and/or social anxiety, and 
over 30% report symptoms of PTSD (Birchwood, 2003; Mueser & Rosenberg, 2003).  
Indeed, the emergence of a psychotic disorder can be extremely jarring to an individual, not 
only forcing him or her to cope with the confusion and uncertainty of the present, but to 
potentially re-evaluate future plans and goals and struggle to adapt to his or her illness 
(McGlashan, 1994; McGorry, 1992). 
 The presence of depression following a psychotic episode (i.e., post-psychotic 
depression; PPD) has been found in at least 50% of individuals recovering from their first 
episode and is more common in patients experiencing early psychosis than in patients with 
more chronic psychotic disorders (Addington, Addington, & Patten, 1998).  In addition, the 
presence of PPD significantly increases the risk of suicide, which is especially high following 
a first episode (Addington, Williams, Young, & Addington, 2004; Birchwood, Iqbal, 
Chadwick, & Trower, 2000; Power, 2004).  People who develop PPD are more likely to have 
experienced greater feelings of loss, humiliation, entrapment, and self-criticism following a 
first episode of psychosis, and are more likely to display greater insight and foresee lower-
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status roles for themselves in the future (Iqbal, Birchwood, Chadwick, & Trower, 2000; 
McGorry, 1992). 
 Finally, significant functional impairments are present at the first episode of 
psychosis, and are likely to emerge in the prodromal phase of the illness (Addington, Young, 
& Addington, 2003; Grant et al., 2001; Häfner et al., 1999).  Indeed, the typical emergence of 
psychosis in late adolescence/early adulthood results in affected individuals’ being 
developmentally “out-of-sync” with their peers, and is likely to cause a significant disruption 
in the normal psychosocial trajectory (EPPIC, 2001).  This is powerfully illustrated in the 
first-person account of an individual with schizophrenia describing her first episode: “During 
my late teens and early 20s, when my age demanded that I date and develop social skills, my 
illness required that I spend my adolescence on psychiatric wards.  To this day I mourn the 
loss of those years” (Leete, 1987, p. 487). 
 Functional impairments in early psychosis include impoverished social networks and 
deficits in interpersonal functioning (Erickson, Beiser, Iacono, Fleming, & Lin, 1989; Grant 
et al., 2001), as well as poor academic and occupational functioning (Gupta et al., 1997; 
Svedberg et al., 2001).  Consistent with these impairments, reduced quality of life is typical 
of first episode samples (Ho et al., 1998; Priebe, Roeder-Wanner, & Kaiser, 2000; Shtasel et 
al., 1992).  In fact, subjective quality of life may be lower in individuals with first episode 
psychosis compared with more chronic patients (Priebe et al., 2000). 
 There is also strong evidence that functional deficits persist despite symptom 
remission in early psychosis (Sheitman et al., 1997).  For example, Tohen and colleagues 
(2000) followed 257 individuals recovering from an initial episode of psychosis for six 
months, and measured levels of both symptomatic and functional recovery.  While 77% of 
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individuals achieved symptomatic recovery by six months, only 30% of individuals were 
able to achieve functional recovery (i.e., return to baseline levels of vocational and/or 
residential status).  Similarly, Whitehorn and colleagues (2002) followed 103 first episode 
patients during their recovery from acute psychosis, and found that 66% of patients had 
achieved symptomatic recovery by six months, while only 30% of the sample had achieved 
functional recovery.  In a longer-term follow-up study, Robinson and colleagues (2004) 
tracked 118 first episode patients for five years, and found that almost 50% of individuals 
achieved sustained symptom remission, while only 25% achieved sustained functional 
recovery dur ing that same time period.  In another long-term follow-up, Svedberg et al. 
(2001) found that 73% of their sample had significant occupational impairments and 64% 
had ongoing deficits in overall social functioning at five years following the first episode. 
 Thus, functional impairments are pervasive and disabling in early psychosis, and 
remain relatively stable over the course of the illness, despite symptomatic recovery 
following treatment with antipsychotic medication (Priebe et al., 2000; Robinson, Woerner, 
Alvir, Geisler et al., 1999).  This is particularly concerning as deficits in social functioning 
and impoverished social networks have been associated with greater risk for relapse and 
poorer long-term prognosis (Birchwood et al., 1998; Erickson et al., 1989; Hoffmann & 
Kupper, 2002).  A primary goal of treatment in the management of first episode psychosis, 
therefore, should be to improve social and occupational functioning and to increase 
subjective quality of life (Falloon et al., 1998; McGorry et al., 2003; Spencer, Birchwood, & 
McGovern, 2001). 
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Psychosocial Treatment of First Episode Psychosis 
 The foregoing discussion indicates that pharmacotherapy is necessary but not 
sufficient in the effective management of early psychosis, especially with respect to 
preventing relapse, facilitating psychological adjustment, and assuring functional recovery.  
Consequently, there has been growing interest in employing adjunctive psychosocial 
interventions in early psychosis to address these and other areas of concern for individuals 
recovering from a first episode (Falloon et al., 1998; Spencer et al., 2001).  Indeed, 
psychosocial interventions are now recommended as a best practice in the management of 
first episode psychosis (International Early Psychosis Association Writing Group, 2005; 
McGorry et al., 2003). 
There has been a surge of research on psychosocial interventions in early psychosis 
over the last 15 years, and published results have been promising (see reviews by Haddock & 
Lewis, 2005; Malla, Norman, & Joober, 2005; Penn, Waldheter, Perkins, Mueser, & 
Lieberman, 2005).  In general, the literature on psychosocial interventions for first episode 
psychosis can be conceptualized as constituting two broad categories: 1) studies evaluating 
comprehensive (i.e., multi-element) interventions, which typically include community 
outreach/early detection efforts (to reduce DUP), in- and outpatient individual, group, and/or 
family therapy, and case management, in addition to pharmacological treatment, and 2) 
studies evaluating specific psychosocial interventions (e.g., individual cognitive behavioral 
therapy).  The extant literature on psychosocial interventions for early psychosis is reviewed 
below in light of these two categories, with an emphasis on studies of specific interventions. 
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Multi-element Interventions 
 Multi-element programs offer a comprehensive array of specialized in- and outpatient 
services designed for individuals experiencing first episode psychosis, and emphasize both 
symptomatic and functional recovery.  Further, many of the issues that are particularly 
problematic among young individuals experiencing psychosis (e.g., substance abuse, 
suicidality, engagement with the mental health system) are addressed through a variety of 
targeted therapeutic approaches.  Table 1 provides general information about several multi-
element programs and their respective components (for a full description of these and 
additional programs, see Edwards, Harris, & Bapat, 2005; Edwards & McGorry, 2002).  The 
Early Psychosis Prevention and Intervention Centre (EPPIC) in Australia is an exemplar of 
multi-element care for early psychosis.  The Prevention and Early Intervention Program for 
Psychosis (PEPP) and Calgary Early Psychosis Treatment Program (EPTP) are additional 
examples of established early intervention centers (Edwards & McGorry, 2002).  Further, 
there have been several large-scale efforts to evaluate the effectiveness of multi-element 
treatment approaches for early psychosis delivered in the context of existing systems of care 
(e.g., Cullberg, Levander, Holmqvist, Mattsson, & Wieselgren, 2002; Johannessen, Larsen, 
McGlashan, & Vaglum, 2000; Nordentoft, Jeppesen, Kassow et al., 2002). 
 The multi-element model of care for early psychosis has only been in existence for a 
little over a decade, but has already garnered significant research support across a variety of 
programs.  It should be noted that randomized controlled designs are the exception rather 
than the rule in multi-element research (e.g., Craig et al., 2004; Nordentoft, Jeppesen, 
Kassow et al., 2002).  Indeed, Edwards et al. (2005) describe the difficulties in conducting 
experimental research with multi-element programs, including community concerns 
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regarding withholding comprehensive services from patients and negative feelings of staff 
who are providing control conditions.  While additional programs are currently being 
evaluated in randomized controlled designs (e.g., EPPIC; Edwards & McGorry, 2002), the 
majority of published research in this area has utilized quasi-experimental and pre-post 
designs to evaluate a program’s effectiveness.  Accordingly, one cannot control for factors 
such as cohort effects or selection bias (in the case of non-randomized group assignment, 
including historical control groups) or spontaneous remission and/or therapeutic attention (in 
the case of single-group, pre-post studies).  Thus, findings should be viewed with caution.  
Nevertheless, data emerging from these interventions have been encouraging. 
In general, multi-element interventions for early psychosis have been associated with 
positive and negative symptom reduction and/or remission (Addington, Leriger, & 
Addington, 2003; Malla, Norman, Manchanda, McLean et al., 2002; Malla, Norman, 
Manchanda, & Townsend, 2002; Malla, Norman, McLean, & McIntosh, 2001; McGorry, 
Edwards, Mihalopoulos, Harrigan, & Jackson, 1996; Nordentoft, Jeppesen, Kassow et al., 
2002; Power et al., 1998), improved quality of life and social functioning (Addington, Young 
et al., 2003; Carbone et al., 1999; Malla, Norman, Manchanda, & Townsend, 2002; Malla et 
al., 2001; McGorry et al., 1996; Nordentoft, Jeppesen, Kassow et al., 2002), improved 
cognitive functioning (Malla, Norman, Manchanda, & Townsend, 2002), reduced DUP 
(Larsen et al., 2001), low rates of hospital admissions (Craig et al., 2004; Cullberg et al., 
2002; Malla, Norman, Manchanda, McLean et al., 2002; McGorry et al., 1996), improved 
insight (Mintz, Addington, & Addington, 2004), high treatment satisfaction (Cullberg et al., 
2002), less time spent in the hospital (Cullberg et al., 2002; McGorry et al., 1996), decreased 
substance abuse (Addington & Addington, 2001), fewer self-harm behaviors (Addington et 
  
  
19 
al., 2004; Nordentoft, Jeppesen, Abel et al., 2002; Power et al., 1998), and reduced trauma 
secondary to psychosis and hospitalization (McGorry et al., 1996).  It should be noted that 
the foregoing results primarily refer to one-year outcomes; longer-term benefits conferred by 
multi-element programs have not been widely reported.  Finally, a recent study suggests that 
these comprehensive and specialized first episode services are likely to yield superior 
outcomes (e.g., shorter DUP, fewer inpatient admissions, less time in the hospital) when 
compared with generic mental health services (Yung, Organ, & Harris, 2003). 
One important caveat regarding multi-element interventions is that the scope of these 
programs makes them difficult to implement on a widespread basis, particularly in countries 
whose public health care systems do not support the necessary infrastructure, such as the 
United States (Jarskog, Mattioli, Perkins, & Lieberman, 2000).  Indeed, given the wide range 
of services offered in these programs, it would be helpful to isolate the “effective 
ingredients” when evaluating a program’s utility.  Understanding which elements are critical 
can help inform program development in areas currently lacking such specialized early 
psychosis services, and there should be a focus on developing and evaluating treatments that 
can be integrated into the existing mental health system.  Studies evaluating specific 
psychosocial interventions can be quite helpful in this regard, and will be the focus of the 
remainder of this report. 
Specific Psychosocial Interventions 
 The studies reviewed below evaluated the effectiveness and relative utility of specific 
psychosocial interventions, rather than assessing the effects of a comprehensive, multi-
element intervention as a whole.  These interventions were offered in addition to 
pharmacological treatment and, in some cases, other services as well (e.g., case 
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management).  Examination of Table 2 reveals that several randomized controlled trials have 
been conducted with respect to individual cognitive-behavioral therapy (CBT) in early 
psychosis, but less controlled research has evaluated group and family interventions.  
Findings from many of these studies have been promising; results are discussed in more 
detail below.   
 Individual therapy.  Individual therapy for first episode psychosis has been examined 
both for facilitating recovery from acute psychosis as well as for improving longer-term 
outcome following remission of acute psychosis.  With respect to the former, the Study of 
Cognitive Reality Alignment Therapy in Early Schizophrenia (SoCRATES) was a large, 
multi-site randomized-controlled trial of CBT in the treatment of recent onset acute 
psychosis.  Based on a pilot study by Haddock et al. (1999), Lewis and colleagues (2002) 
randomly assigned 309 individuals who had either a first (83%) or second psychiatric 
admission for psychosis to either 5-week CBT and routine care, 5-week supportive 
counseling (SC) and routine care, or 5-week routine care alone (RC).  While all groups 
improved over the course of treatment, there was a trend for the CBT group to improve the 
fastest.  Further, auditory hallucinations improved significantly faster in the CBT group 
relative to the SC group.  There were no significant group differences, however, in symptoms 
at the end of treatment.  At 18-month follow-up, Tarrier and colleagues (2004) found 
significant advantages for both CBT and SC in reducing positive symptoms relative to RC.  
Further, auditory hallucinations responded better to CBT relative to SC.  However, there 
were no group differences in relapse rates, with overall rates of relapse being high across the 
total sample.  Tarrier et al. hypothesized that factors such as short duration of treatment, 
failure of treatment effects to generalize outside the hospital, and potential exposure to 
  
  
21 
environmental stressors post-discharge may explain the lack of an impact on relapse 
conferred by CBT or SC.  Nevertheless, these results suggest that individual therapy (i.e., 
CBT or SC) may have beneficial long-term effects on positive symptom reduction in early 
psychosis. 
 Promising results have also been reported with respect to CBT conducted during the 
period of recovery following reduction of acute psychotic symptoms.  Jackson and 
colleagues (1998) conducted a prospective study of Cognitively-Oriented Psychotherapy for 
Early Psychosis (COPE) with 80 individuals in the EPPIC program who were experiencing 
non-affective and affective first episode psychosis.  COPE promotes adjustment to one’s 
illness, helps individuals resume developmental tasks, and focuses on overall recovery, in 
addition to targeting secondary morbidity (i.e., depression, anxiety).  Forty-four individuals 
voluntarily received COPE as part of their outpatient care, 21 refused but received all other 
EPPIC services, and 15 individuals received inpatient care only with no additional services 
following discharge (i.e., “control group”).  At the end of treatment, COPE patients 
performed significantly better than the control group on measures of insight and attitudes 
toward treatment, adaptation to illness, quality of life, and negative symptoms, but only 
significantly out-performed the refusal group with respect to adaptation to illness.  There 
were no significant differences in relapse rates between the three groups.  At one year 
following treatment, the COPE group maintained significantly better adaptation to their 
illness relative to the refusal group; however, group differences were not maintained for other 
outcomes, and there were no group differences in relapse rates or time to re-admission 
(Jackson, McGorry, Henry et al., 2001).  At four year follow-up, no significant group 
differences remained (Jackson et al., 2005).  The authors hypothesized that poor follow-up 
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rates may have weakened power to detect group differences.  While these findings are based 
on a quasi-experimental design and need to be interpreted with caution, results suggest that 
individual CBT may have short-term (i.e., at least one year) benefits with respect to assisting 
patients adjust to their illness following first-episode symptom remission. 
Individual CBT approaches have been developed to target specific challenges facing 
patients experiencing first episode psychosis, such as suicidality, substance abuse, and 
persistent symptoms.  In a study focusing on suicidal ideation and behavior in early 
psychosis, Power and colleagues (2003) randomly assigned 56 suicidal individuals with non-
affective and affective first episode psychosis in the EPPIC program to either “LifeSPAN 
therapy” or “no LifeSPAN therapy”; both groups continued to receive all other EPPIC 
services.  LifeSPAN therapy is based on COPE as well as cognitive therapy for suicide, and 
emphasizes distress management, problem-solving skills, identification of warning signs, and 
development of an after-care plan.  In addition, low self-esteem and feelings of hopelessness 
are specifically targeted.  In this study, both groups improved on ratings of suicidal ideation 
and number of suicide attempts.  However, the results showed an advantage for LifeSPAN 
therapy on self- reported hopelessness and quality of life at both 10-weeks post-treatment and 
six-month follow-up.  Power et al. concluded that adding CBT to treatment for first episode 
psychosis may lead to significant improvements in factors associated with suicide, such as 
hopelessness. 
Results from the SoCRATES trial indicate that suicidal behavior in individuals with 
recent onset acute symptoms decreased sharply in all groups (both treatment and controls) 
after hospital admission and treatment (Tarrier, Haddock, Lewis, Drake, & Gregg, 2006).  
Furthermore, there were no significant differences in suicidal behavior between the three 
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groups (CBT, supportive counseling, and routine care) at 6 weeks, 3 months, and 18 months.  
Therefore, it may be that CBT interventions which specifically target hopelessness, self-
esteem, and other suicidal antecedents will have a stronger impact on suicidal behavior than 
generic CBT interventions. 
Edwards and colleagues at EPPIC have developed CBT-based interventions targeting 
substance use and persistent psychotic symptoms (Edwards, Wade, Herrman-Doig, & Gee, 
2004; Elkins et al., 2004).  The “Cannabis and Psychosis” (CAP) intervention focuses on 
reducing problematic cannabis use in individuals with first episode psychosis, and consists of 
psychoeducation, motivational interviewing, goal setting, and discussion about goal 
achievement and relapse prevention.  In a randomized controlled trial, cannabis-using 
individuals receiving EPPIC services were randomized to either 10 sessions of CAP therapy 
in addition to standard care or 10 sessions of psychoeducation in addition to standard care.  
Both groups demonstrated a significant decrease in cannabis use at 6 months, and there were 
no clear advantages for CAP over psychoeducation alone (Edwards et al., 2006; Edwards et 
al., 2003).  Edwards et al. suggest that the control condition may have been too ‘active’ to 
detect any differences in the study, and that cannabis- focused interventions may have 
maximum impact for individuals who are cannabis-dependent.  However, these results 
suggest that straightforward interventions such as psychoeducation should be further 
investigated as a means to reduce cannabis use in early psychosis. 
Motivational interviewing has also been adapted with some success for substance 
abuse in early psychosis.  Kavanagh et al. (2004) randomized 25 inpatients with early 
psychosis (those who had been ill fewer than 3 years with fewer than 2 episodes of 
psychosis) to receive either standard care or a brief motivational intervention called “Start 
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Over and Survive” (SOS). This treatment was comprised of 3 hours of individual treatment 
over the course of 6-9 sessions that were completed in 7-10 days. Follow-ups were obtained 
at 6 weeks and 3, 6, and 12 months. At 6 months, all patients treated with SOS had positive 
outcomes (defined as either being abstinent, having non-problematic substance abuse across 
all substances, or a reduction of at least 50% in the use of all problematic substances plus 
reductions of associated problems), whereas only 58% of patients receiving standard care had 
positive outcomes. These differences were no longer significant at 12 months, and results are 
tempered by the fact that more SOS participants lived with a family member or partner, 
which was also associated with better outcomes.  Though implications of this trial are limited 
by its small sample size and should be interpreted with caution, it appears that individual 
psychosocial interventions to address substance abuse in early psychosis are feasible and 
promising. 
Edwards and colleagues at EPPIC have also developed “Systematic Treatment of 
Persistent Psychosis” (STOPP), given that approximately 20% of individuals with first 
episode psychosis may experience persistent psychotic symptoms (Edwards et al., 2002).  
STOPP is based on COPE, and is designed to facilitate recovery in patients experiencing 
persistent positive symptoms.  A randomized controlled trial evaluating the relative and 
combined effects of the atypical antipsychotic clozapine and STOPP in the treatment of 
individuals with persistent symptoms is currently being conducted at EPPIC (Edwards et al., 
2004). 
Other randomized-controlled studies of individual CBT for first episode psychosis 
have demonstrated benefits over routine care with respect to fewer days spent in the hospital 
(Jolley et al., 2003), and reduced psychotic symptoms, fewer hospital admissions, increased 
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insight, and better treatment adherence (Wang et al., 2003).  Thus, the foregoing findings 
suggest that individual CBT may provide some benefit in the treatment of first episode 
psychosis, particularly in the areas of positive symptom reduction, adaptation to one’s illness, 
and improvements in subjective quality of life.  Most studies have not shown individual 
therapy to be effective in reducing relapses or re-hospitalizations.  Finally, long-term findings 
are mixed; follow-up data reported thus far have demonstrated some long-term benefits 
associated with individual therapy (e.g., Tarrier et al., 2004), although also suggest that some 
initial treatment gains may not persist over time (e.g., Jackson et al., 2005). 
Group and family therapy.  Unlike individual therapy, there are no randomized-
controlled studies examining the efficacy of group treatment for first episode psychosis.  
Quasi-experimental research has demonstrated benefits of group therapy with respect to 
prevention of illness-related deterioration and disability, especially for individuals with poor 
premorbid functioning (Albiston, Francey, & Harrigan, 1998).  Additional uncontrolled 
studies have reported improved treatment adherence (Miller & Mason, 2001) and increased 
treatment satisfaction (Lecomte, Leclerc, Wykes, & Lecomte, 2003) associated with group 
participation.  However, given the uncontrolled nature of these studies, findings need to be 
interpreted with caution. 
While there is a substantial research base documenting the efficacy of family therapy 
for chronic schizophrenia (Pilling, Bebbington, Kuipers, Garety, Geddes, Orbach et al., 
2002), there are few well-controlled studies of family therapy for first episode psychosis.  
Further, several of these studies have yielded disappointing results.  For example, Linszen 
and colleagues (1996) randomly assigned 76 outpatients with non-affective recent-onset 
psychosis to 12 months of behavioral family therapy (focusing on communication and 
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problem-solving skills training) and individual-oriented treatment (focusing on relapse 
prevention and psychoeducation), or individual-oriented treatment without family therapy.  
Both groups had recently been discharged after three months of inpatient treatment 
emphasizing integrated psychosocial and pharmacological treatment, and were current ly 
receiving outpatient medication management.  After one year, there was no differential effect 
of the family treatment on relapse; both groups had similar relapse rates, and the overall 
relapse rate for the sample was low (i.e., 16%).  Five-year follow-up also found no added 
benefit of family treatment over individual treatment on relapse rates, and found that 65% of 
patients in the total sample with non-chronic symptoms relapsed at least once over the course 
of five years.  In addition, this study found no differential effect of family treatment on social 
functioning or expressed emotion.  However, individuals who received family treatment 
spent significantly less time in hospitals and/or shelters (Lenior, Dingemans, Linszen, De 
Haan, & Schene, 2001; Lenior, Dingemans, Schene, Hart, & Linszen, 2002).  A similar study 
by the same research group also found no differential effect of family treatment on relapse 
rates or expressed emotion (Nugter, Dingemans, Van Der Does, Linszen, & Gersons, 1997).  
Finally, a recent randomized controlled trial comparing routine care with a brief family 
intervention emphasizing psychoeducation, support, and advice reported no added benefit of 
the family intervention on the number of days that patients spent in the hospital or on family 
satisfaction with services over a nine-month follow-up (Leavey et al., 2004). 
Some research on family therapy for early psychosis has demonstrated more positive 
results.   For example, Zhang and colleagues (1994) randomly assigned 83 outpatients with 
first episode psychosis to 18 months of family therapy and routine care, or routine care alone.  
The family therapy intervention consisted of family groups and individual family therapy 
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sessions, and emphasized psychoeducation, identification of warning signs, stress 
management, importance of attributing maladaptive behavior to illness (rather than 
personality or “laziness”), communication-skills training and reduction of high expressed 
emotion (i.e., decreasing familial criticism, hostility, and overinvolvement).  There was 
contact with families at least once every three months, and families that did not attend 
appointments were visited in their homes.  Results showed that the family intervention was 
associated with a significantly lower rate of hospital readmissions and fewer days spent in the 
hospital.  Indeed, Zhang et al. concluded that patients not receiving the family intervention 
were 3.5 times as likely to be re-admitted to the hospital during the study period as patients 
who did receive family therapy.  This effect remained even after controlling for differences 
in medication compliance.  Further, patients receiving family therapy that were not re-
admitted to the hospital demonstrated significant improvements in positive symptoms and 
social functioning.  Additional research has reported similar favorable outcomes associated 
with family treatment, such as fewer hospital admissions, less time spent in the hospital, and 
symptom reduction (Lehtinen, 1993). 
Thus, while some research has found family interventions in early psychosis to be 
beneficial with respect to reducing relapse and improving clinical and functional status (e.g., 
Zhang et al., 1994), other findings have not been as encouraging (e.g., Linszen et al., 1996).  
More empirical work needs to be done before any firm conclusions can be made. 
Finally, Drury and colleagues (1996a, 1996b) specifically evaluated the effects of a 
multi-modal therapy approach combining individual and group CBT with family therapy in 
the treatment of recent onset acute psychosis.  In a randomized controlled trial, the 
combination treatment, compared with basic support and recreational activities, yielded faster 
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and greater improvements of positive symptoms, reduced recovery time by 25-50%, and led 
to improvements in insight, dysphoria, and “low-level” psychotic thinking (e.g., 
suspiciousness). In a five-year follow-up, Drury et al. (2000) reported enduring positive 
effects for the combination therapy group relative to the control group; however, these 
benefits were predominantly observed in individuals who had experienced at most one 
relapse over the course of follow-up.  Long-term benefits in this sub-sample included fewer 
positive symptoms, less delusional conviction and thought disorder, and better subjective 
“control over illness.”  While these findings are positive, this study has been criticized for 
methodological flaws in its design, such as non-blinded assessments (Tarrier, 2005) and 
baseline differences in medication dosages between the two groups (Turkington, Dudley, 
Warman, & Beck, 2004). 
Psychosocial Treatment of First Episode Psychosis: Conclusions 
The findings reviewed suggest that adjunctive psychosocial interventions with 
patients experiencing early psychosis may be beneficial across a variety of domains, and can 
assist with symptomatic and functional recovery.  With respect to current research on specific 
psychosocial interventions in particular, support for individual CBT in early psychosis is 
modest yet encouraging, especially regarding symptom improvements (particularly positive 
symptoms), adaptation to one’s illness, and increased subjective quality of life (Jackson, 
McGorry, Henry et al., 2001; Power et al., 2003; Tarrier et al., 2004).  No firm conclusions 
can yet be drawn from the literature on group and family therapies for this population.  
Group therapy is a widely used treatment modality for early psychosis, but no randomized 
controlled trials have been conducted.  Research findings on family therapy in early 
psychosis have been mixed, with some studies documenting benefits with respect to 
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symptoms, social functioning, and likelihood of re-hospitalization (e.g., Zhang et al., 1994), 
and other studies reporting less favorable results (e.g., Linszen et al., 1996).  One possible 
interpretation of these findings is that family interventions are indeed beneficial to 
individuals in early psychosis, although may not add significant benefit above and beyond 
concurrent individual therapy. 
Thus, available evidence suggests that individual CBT may play a role in facilitating 
recovery from a first episode of psychosis.  Nevertheless, the targets of existing individual 
therapy approaches for this population are quite narrowly defined, and each treatment only 
addresses one or two areas of concern for individuals recovering from a first episode, such as 
symptoms (e.g., Lewis et al., 2002) or substance use (e.g., Edwards et al., 2003).  Of course, 
these are important foci in therapy; however, as discussed above, individua ls with first 
episode psychosis experience many challenges, all of which can impede progress towards 
recovery.  Existing treatments may not be comprehensive or flexible enough to meet the 
needs of this population. 
In addition, current single-element treatments fail to effectively target functional 
recovery after a first episode.  As discussed above, it has been well documented that 
significant functional deficits (e.g., interpersonal relationships, occupational functioning) are 
prevalent early in the course of psychosis, persist despite symptom remission, and are 
associated with a poor long-term prognosis (Birchwood et al., 1998; Grant et al., 2001; 
Tohen et al., 2000).  These deficits need to be a major focus of treatment in early psychosis 
(Addington & Gleeson, 2005). 
In summary, in order to optimize the likelihood of successful recovery, individual 
therapy for first episode psychosis needs to take an integrative approach to psychosocial 
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treatment, drawing on a variety of empirically-validated treatment approaches to address the 
variety of cha llenges that individuals with first episode psychosis may experience, such as 
medication non-adherence, high relapse risk, substance use, residual positive and negative 
symptoms, stigma and injuries to self-esteem, and functional impairments.  To date, there are 
no standardized individual treatments that comprehensively target all of these areas of 
concern in a single intervention. 
Facilitators of Recovery from First Episode Psychosis 
 The foregoing discussion has highlighted the limitations of existing psychosocial 
treatments with respect to addressing the variety of challenges facing individuals with first 
episode psychosis, in particular functional deficits.  To be sure, all of these challenges are 
likely to be barriers to recovery.  Further, targeting these areas in the context of a therapeutic 
intervention is consistent with the literature examining facilitators of recovery, or predictors 
of good outcome in schizophrenia and other psychotic disorders.  Indeed, if one is to develop 
a truly effective and comprehensive treatment for individuals recovering from a first episode 
of psychosis, it is essential to consider all relevant predictors of outcome, particularly those 
that are potentially malleable and responsive to psychosocial intervention. 
 “Recovery” from severe mental illness has been defined in different ways in recent 
years.  Nevertheless, most definitions emphasize three broad elements of meaningful 
recovery: illness-management (i.e., through medication adherence, increased understanding 
of one’s illness, and effective coping regarding symptoms, stress, and the threat of relapse), 
optimism and a sense of control over one’s illness, and functional recovery (i.e., meaningful 
relationships, meaningful roles at work or school, independent living, leisure/recreation time) 
(Liberman, Kopelowicz, Ventura, & Gutkind, 2002; Noordsy et al., 2002; Spaniol et al., 
  
  
31 
2002).  In general, in order to facilitate the recovery process, clients should be encouraged to 
set personally relevant goals, problem-solve regarding potential barriers, and enhance their 
self-efficacy (Hoffmann & Kupper, 2002; Mueser et al., 2002; Noordsy et al., 2002). 
 There have been a number of factors identified as specific facilitators of recovery, or 
predictors of good outcome, in schizophrenia and early psychosis, in particular (see Table 3).  
Some of these are fixed, or unchangeable by the time an individual presents for therapy 
following resolution of an initial psychotic episode; however, many of these predictors are 
malleable and thus potential targets of treatment.  Fixed facilitators of recovery include: good 
premorbid functioning (Addington, van Mastrigt, & Addington, 2003; Gupta, 
Rajaprabhakaran, Arndt, Flaum, & Andreasen, 1995; Hoffmann & Kupper, 2002; Huber et 
al., 1975; Malla, Norman, Manchanda, Ahmed et al., 2002; Malla et al., 2004; Perkins et al., 
2004; Rabinowitz et al., 2002), female gender (Szymanski et al., 1995), later age of illness 
onset, higher socioeconomic status (Spaniol et al., 2002), shorter DUP (Lieberman, Perkins 
et al., 2001; Norman & Malla, 2001), and a better initial response to antipsychotic medication 
(Hoffmann & Kupper, 2002; Liberman et al., 2002; Lieberman et al., 1993). 
 There are several facilitators of recovery in early psychosis that are malleable and 
potentially amenable to psychosocial intervention.  These include basic illness-management 
strategies (e.g., medication adherence, relapse prevention efforts), abstinence from substance 
use, effective management of residual positive and negative symptoms, optimism and high 
self-esteem, pursuit of personally relevant goals, and good social/occupationa l functioning 
(Edwards et al., 2004; Erickson et al., 1989; Hoffmann & Kupper, 2002; Liberman et al., 
2002; Linszen et al., 1994; Noordsy et al., 2002; Spaniol et al., 2002).  These predictors of 
favorable outcome are discussed in greater detail below. 
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 Factors associated with effective illness self-management, including medication 
adherence, skills for coping with stress, a relapse prevention plan, and basic knowledge of 
mental illness, have all been identified as facilitators of recovery in psychosis (Birchwood & 
Spencer, 2001; Hoffmann & Kupper, 2002; Mueser et al., 2002; Noordsy et al., 2002; 
Spaniol et al., 2002).  In particular, close adherence to one’s prescribed medication regimen 
has been consistently associated with better outcomes across the psychotic disorders 
(Bradford et al., 2003; Gitlin et al., 2001; Robinson, Woerner, Alvir, Bilder et al., 1999).  
Non-adherence is common in early psychosis (e.g., Coldham et al., 2002) and is mediated by 
a variety of factors, such as limited insight, side effects, psychotic symptoms (e.g., paranoia 
or grandiosity), cognitive disorganization, comorbid substance use, limited financial 
resources, and negative beliefs about treatment (Fenton et al., 1997; Gray et al., 2002; 
McGorry, 1992).  Efforts to improve medication adherence are likely to result in significantly 
reduced rates of relapse and associated treatment resistance (Gitlin et al., 2001; Lieberman et 
al., 1998). 
 Substance use in people with schizophrenia has been associated with increased 
symptomatology, greater rates of relapse, poorer treatment response, increased medication 
non-adherence, impaired social functioning, elevated levels of anxiety and depression, 
occurrence of antisocial behavior, homelessness, victimization, and the loss of social support 
and financial resources (Addington & Addington, 1998; Bellack & DiClemente, 1999; 
DeQuardo, Carpenter, & Tandon, 1994; Drake, Mueser, Brunette, & McHugo, 2004; Elkins 
et al., 2004; Green et al., 2004; Hambrecht & Häfner, 1996; Kovasznay et al., 1993; Linszen 
et al., 1994; Mueser & McGurk, 2004; Silver & Abboud, 1994).  Consistent with these data, 
abstinence from substance use has been determined to be a powerful facilitator of recovery in 
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psychosis, and has been deemed a key target of psychosocial interventions (Barrowclough et 
al., 2001; Bellack & DiClemente, 1999; Hoffmann & Kupper, 2002; Mueser & Bond, 2000; 
Spaniol et al., 2002).  Indeed, in a qualitative study of recovery from schizophrenia, Spaniol 
and colleagues emphasized the fact that comorbid substance abuse, when present, tended to 
dominate the clinical picture, became the predominant disabling condition even during active 
phases of psychosis, and was a formidable obstacle on the road to recovery for the majority 
of individuals in their sample. 
 Residual positive and negative symptoms have been associated with greater levels of 
overall distress and social/occupational impairment, as well as lower subjective quality of life 
(Edwards et al., 2002; Edwards et al., 1999; Malla et al., 2004; Mayerhoff et al., 1994).  
Reduction of persistent symptoms has been associated with highly significant reductions in 
depression and hopelessness among individuals with schizophrenia (Tarrier, 2005), and is 
likely to be a significant facilitator of improved occupational functioning (Racenstein et al., 
2002).  Indeed, in their operationalization of recovery from schizophrenia, Liberman and 
colleagues (2002) note sustained symptom remission as a key criterion.  Thus, residual 
positive and negative symptoms represent an important and malleable target of psychosocial 
interventions, and effective management of these symptoms is deemed critical to the 
recovery process (Hoffmann & Kupper, 2002). 
 The experience of an initial psychotic episode can do significant damage to an 
individual’s self-esteem, sense of agency, hopes, dreams, and aspirations.  As described 
above, depression following resolution of a first episode is very common, and is most often 
associated with feelings of loss, entrapment, humiliation, and self-criticism (Addington et al., 
1998; Birchwood, 2003; Iqbal et al., 2000).  Low self-esteem has also been linked to 
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increases in symptomatology and social/occupational functioning impairments.  For example, 
in a study of individuals with recent onset psychosis, negative self-evaluation mediated the 
relationship between familial criticism and exacerbation of positive symptoms 
(Barrowclough et al., 2003).  This is consistent with earlier work demonstrating the 
relationship between low self-esteem and the formation and maintenance of psychotic 
symptoms (e.g., persecutory delusions or auditory hallucinations with negative content; 
Garety, Kuipers, Fowler, Freeman, & Bebbington, 2001; Kinderman & Bentall, 1996).  In 
addition, Roe (2003) found that changes in self-esteem over one year following hospital 
discharge were significantly associated with overall functioning and outcome at the end of 
the year among a sample of individuals with chronic non-affective and affective psychotic 
disorders.  Finally, Bassett and colleagues (2001), in a survey of individuals recovering from 
their first episode of psychosis, found that primary barriers to occupational functioning 
included low self-confidence, low self-esteem, and stigma.  Indeed, the stigma of severe 
mental illness is pervasive in society, and young people experiencing the early phases of 
psychosis are particularly vulnerable to its pernicious effects on self-esteem and self-concept 
(Birchwood et al., 1998; Edwards & McGorry, 2002; EPPIC, 2001; McGorry, 1992; Torrey, 
1995). 
 These findings converge with the emphasis in the treatment literature on boosting 
self-esteem, fostering hope and optimism, and encouraging adaptation to one’s illness, 
particularly following a first episode (Birchwood et al., 1998; Jackson et al., 1998; Jackson, 
McGorry, Henry et al., 2001; Leete, 1987; McGlashan, 1994; McGorry, 1992, 2004).  The 
maintenance of hope and enhancement of self-esteem have been identified as critical 
facilitators of recovery in psychosis, and represent potentially malleable targets for 
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psychosocial intervention (Barrowclough et al., 2003; Hall & Tarrier, 2003; Hoffmann & 
Kupper, 2002; Lecomte et al., 1999; Noordsy et al., 2002; Roe, 2003).  Consistent with this, 
the pursuit of personally relevant goals following a first episode is imperative as both a 
source and reinforcer of social agency, self-esteem, and optimism (McGorry, 1992; Mueser 
et al., 2002; Noordsy et al., 2002).  Indeed, Noordsy et al. emphasize the powerful role that 
goal-setting can play in the development and maintenance of motivation to recover from 
severe mental illness. 
 Finally, the prospects of a successful recovery after an initial episode of psychosis are 
significantly challenged by the presence of pervasive and enduring deficits in functional 
abilities that persist despite symptom reduction (Grant et al., 2001; Gupta et al., 1997; Ho et 
al., 1998; Robinson et al., 2004; Tohen et al., 2000).  In a broad sense, functional abilities 
comprise academic/occupational functioning, interpersonal functioning, pursuit of leisure 
activities, and adaptive living skills (Liberman et al., 2002; Noordsy et al., 2002).  Deficits in 
these domains may be secondary to factors such as poor premorbid functioning, repeated 
relapse, active substance use, residual symptoms, cognitive impairments, low self-esteem, or 
stigma, and/or may be primary features of the disease process and associated deterioration 
(Addington, Young et al., 2003; Bassett et al., 2001; EPPIC, 2001; Hambrecht & Häfner, 
1996; Lieberman, 1999; Lieberman, Chakos et al., 2001; Lieberman & Fenton, 2000; 
McGlashan & Johannessen, 1996; McGorry et al., 2000; Perkins et al., 2004; Rabinowitz et 
al., 2002; Racenstein et al., 2002; Salyers & Mueser, 2001). 
 Hoffman and Kupper (2002) have described social competency and interpersonal 
functioning as one of the best predictors of clinical outcome.  Others have also emphasized 
the vital role that improved social/occupational functioning plays both as a key facilitator of 
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the recovery process and as a key outcome measure, or goal of treatment (Addington, Young 
et al., 2003; Birchwood et al., 1998; Erickson et al., 1989; Liberman et al., 2002; Malla, 
Norman, Manchanda, & Townsend, 2002; Mueser et al., 2002; Mueser & McGurk, 2004; 
Noordsy et al., 2002; Spaniol et al., 2002; Spencer et al., 2001).  Indeed, psychosis strikes 
most people in their late teens and early 20s, during a time of significant developmental 
growth and psychosocial changes, such as identity formation and individuation from the 
family, strengthening of connections with peers and exploration of romantic relationships, 
and pursuit of academic/occupational aspirations (Erikson, 1968; Leete, 1987).  Young 
people experiencing their first psychotic episode are therefore at risk for lagging significantly 
behind their peers regarding important milestones, and need phase-specific therapeutic 
intervention designed to minimize further psychosocial deterioration and assist with the re-
learning and/or development of age-appropriate social skills and roles (EPPIC, 2001; Henry, 
2004). 
 In summary, taking facilitators of recovery and barriers to recovery in early psychosis 
into account, the following domains should be addressed in a comprehensive and effective 
psychosocial treatment: illness-management (including psychoeducation, medication 
adherence strategies, and a focus on relapse prevention), substance use, residual symptoms, 
self-esteem, and functional recovery (e.g., social/occupational functioning).  Given the 
heterogeneity inherent to psychotic disorders and early psychosis in particular, the treatment 
should be flexible and tailored to the presenting concerns of the client (Malla & Norman, 
2002; Spaniol et al., 2002).  Above all else, clients recovering from their first episode should 
be encouraged to adapt to their illness, develop increased self-efficacy and hope, and move 
forward by setting and achieving meaningful goals. 
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Introduction of a New Psychosocial Intervention for First Episode Psychosis 
 The foregoing has highlighted the need for early intervention in psychosis, explained 
that psychosocial treatment is a critical adjunct to pharmacotherapy, described the limitations 
of existing psychosocial treatments, and specified the targets of an effective psychosocial 
intervention for individuals recovering from an initial episode of psychosis.  Taking all of 
these factors into account, Penn and colleagues (2005) developed a preliminary version of 
The Graduated Recovery Intervention Program (GRIP) for first episode psychosis.  GRIP is 
a comprehensive yet flexible individual therapy program that addresses the primary areas of 
concern for individuals with early psychosis, and aims to facilitate functional recovery 
following a first episode.  It is comprised of therapeutic strategies and techniques that are 
based on princ iples of CBT (Beck, 1995; Kingdon & Turkington, 2004) and have been 
empirically-validated in the treatment of individuals with chronic schizophrenia.  A brief 
overview of the nature and aims of GRIP, a description of its specific treatment phases, and 
empirical support for each of its elements and prescribed treatment techniques, is provided 
below. 
Treatment Logistics and Clinical Foci 
 GRIP is a modular-based intervention that is administered on an individual, weekly 
basis for up to 36 sessions over nine months.  It is designed for adolescents (older than 18 
years old) and adults who are recovering from an initial episode of non-affective psychosis.  
It is comprised of four treatment phases: (1) engagement and wellness-management, (2) 
substance use, (3) residual symptoms, and (4) functional recovery. 
All clients should receive the ten sessions of Phase 1 (engagement and wellness-
management), and a minimum of two sessions of psychoeducation on substance use and its 
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relationship to recovery in Phase 2.  Therefore, a minimum of 12 therapy sessions is devoted 
to the first two phases of GRIP.  If a client currently has substance use problems, he or she 
will receive up to eight additional sessions of treatment during Phase 2. 
After Phase 2, the clinician can either move to Phase 3, if residual positive and/or 
negative symptoms are present (and are distressing and/or impairing), or directly to Phase 4, 
which focuses on functional recovery.  Therefore, if a client does not have substance use 
problems or residual symptoms, he or she will receive up to 24 sessions of work on 
functional recovery.  Indeed, functional recovery has been identified as a primary goal of 
psychosocial treatment for first episode psychosis (Grant et al., 2001; Hoffmann & Kupper, 
2002; Malla, Norman, Manchanda, & Townsend, 2002; McGorry, 2004; Noordsy et al., 
2002; Spencer et al., 2001).  Accordingly, it is the primary outcome variable for GRIP. 
General Characteristics and Features of GRIP 
Session structure and treatment techniques prescribed in GRIP are based on principles 
of CBT.  As will be described more fully in the following section on specific phases of 
GRIP, cognitive-behavioral therapy approaches have been well-documented as being 
efficacious in the treatment of schizophrenia (e.g., Gould, Mueser, Bolton, Mays, & Goff, 
2001; Rector & Beck, 2001; Tarrier, 2005).  Consistent with the general format of CBT, 
sessions in GRIP are structured in the following way: greeting/check-in, bridge from 
previous session, discussion of agenda for current session, review of previous week’s 
homework assignment, discussion of new material, assignment of new homework, and 
summary/wrap-up (Beck, 1995). 
Homework is an important feature of CBT, and it is an essential component of GRIP.  
Work done outside of the therapy sessions is critical to generalizing skills and concepts 
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discussed in the therapist’s office to a client’s daily life.  Further, assignment of and 
compliance with homework assignments has been statistically associated with treatment 
outcome.  In a meta-analysis of 27 studies of CBT for a variety of clinical problems, 
Kazantzis and colleagues (2000) reported a weighted mean effect size of .36 for the relation 
between use of homework assignments and outcome, and .22 for the relation between 
homework compliance and outcome.  Thus, there is both theoretical and empirical support 
for the use of between-session assignments in facilitating positive change in GRIP. 
In the spirit of promoting generalization and maximizing retention of therapeutic 
gains, clients will be asked to identify a person with whom they live or interact on a regular 
basis to serve as an “indigenous supporter” (Tauber, Wallace, & Lecomte, 2000).  This 
individual will serve as a bridge between the therapist’s office and the client’s daily life.  The 
nature of the relationship between the client and supporter is flexible; however, clients will 
be encouraged to meet regularly with their supporters to discuss material addressed in 
therapy, review homework assignments, and practice relevant skills.  Supporters will be 
encouraged to provide expressive and instrumental support to clients, and to continuously 
promote generalization of therapy material to the client’s natural environment.  They will 
serve as an adjunct member of the client’s treatment team, and will be kept “in the loop” 
regarding therapy progress. 
There is empirical support for the use of indigenous supporters in the treatment of 
psychotic disorders.  In a study of 85 individuals with severe mental illness (75% with non-
affective psychosis) who were receiving treatment in illness-management and social skills 
training, Tauber et al. (2000) found that clients working with an indigenous supporter had 
significantly better interpersonal functioning at both six- and 12-month follow-up than clients 
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without such support.  Further, both clients and supporters were pleased with the nature of 
their relationship and enjoyed meeting regularly.  It is hoped that enlisting the assistance of 
indigenous supporters in GRIP will not only promote generalization of skills, but that it will 
also help to keep clients engaged with treatment services, which is a significant problem in 
this population, yet is essential to assuring positive outcomes (EPPIC, 2001; Linszen, Lenior, 
De Haan, Dingemans, & Gersons, 1998; McGorry, 2004). 
Specific Phases of GRIP 
 Following is a description of each of the specific phases of GRIP (see Table 4), with 
accompanying background and empirical support for pertinent therapeutic techniques. 
 Phase 1: Engagement and wellness-management.  The goals of this phase are: (1) 
engage the client in treatment, (2) provide psychoeducation regarding psychosis and 
antipsychotic medication, (3) identify therapy goals, (4) enhance medication adherence, and 
(5) develop a relapse prevention plan. 
 Effective engagement with clients is essential, and is the first task of the GRIP 
therapist.  This process can be rather difficult with young people recovering from a first 
episode of psychosis due to a variety of factors, including minimal prior experience with the 
mental health system, denial of one’s illness, negative stereotypes of mental illness, and 
normative adolescent (or young adult) resistance to authority (EPPIC, 2001; ORYGEN 
Youth Health, 2004).  Nevertheless, first impressions during this phase are critical at shaping 
clients’ perceptions of the mental health system and determining their likelihood of continued 
engagement with treatment (Birchwood et al., 1998).  Indeed, the establishment and 
maintenance of a strong therapeutic alliance is a very important and highly valued element of 
GRIP, given both the specific needs of a first episode population as well as the general 
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empirical finding that a stronger alliance is associated with better treatment outcomes in both 
psychotic and non-psychotic populations (Frank & Gunderson, 1990; Horvath & Symonds, 
1991; Martin, Garske, & Davis, 2000; Mojtabai, Nicholson, & Carpenter, 1998; Penn et al., 
2004). 
 Initial engagement consists of introducing the overall aims and purpose of GRIP (i.e., 
“pursuing goals, staying out of the hospital, and enhancing quality of life”), describing 
logistical issues (e.g., frequency, duration of meetings), explaining the roles of homework 
and collaborative agenda-setting, getting to know the client, and eliciting the client’s personal 
narrative of his/her illness, including what led up to hospitalization, the na ture of his/her 
symptoms, and his/her understanding of and personal reaction to these events.  In addition, 
the client will be asked to identify somebody who can serve as an “indigenous supporter” 
during the course of therapy (Tauber et al., 2000).   
 Psychoeducation is another early component of GRIP.  The majority of individuals 
recovering from an initial episode of psychosis are greatly confused and anxious about their 
experience.  One primary task of therapy is to assist clients in making sense of their 
experience and in developing a healthy “explanatory model” of their illness (McGorry, 
1992).  The provision of accurate information is critical in this regard.  The early phases of 
GRIP are comprised of psychoeducation on psychosis (i.e., symptoms, possible causes, 
strategies for recovery) and antipsychotic medications (i.e., effectiveness at reducing 
symptoms and relapse risk, possible side effects).  This is an interactive process that strives 
to use the client’s own experiences in order to broaden understanding of psychosis and 
psychiatric treatment.  In addition, given the diagnostic uncertainty inherent to this phase of 
the illness, the term “psychosis” is emphasized over diagnostic labels such as schizophrenia 
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or schizoaffective disorder (Spencer et al., 2001).  The objective for this phase of treatment is 
to correct any misperceptions that the client may have about psychosis, emphasize the high 
likelihood of recovery following a first episode, introduce the stress-vulnerability model, and 
describe the benefits of treatment adherence (EPPIC, 2001; Henry, 2004; Kingdon & 
Turkington, 2004; Turkington et al., 2004).  Overall, there is consistent empirical support for 
the ability of psychoeducation to improve knowledge about mental illness and medication in 
patients with psychotic disorders (Mueser et al., 2002). 
 Functional recovery is a key objective of GRIP, and one key prerequisite for 
successful functional recovery is the identification and pursuit of goals (Noordsy et al., 
2002).  Short-term and long-term goals are identified early on in treatment in order to 
encourage an adaptive and healthy forward- looking focus during recovery, and to provide 
benchmark(s) with which to measure therapeutic progress.  A variety of techniques are 
employed to assist with goal-setting, including the provision of potential functional goal 
targets and the use of “scaling” (i.e., identifying discrepancy between current functioning and 
ideal functioning).  This is a collaborative and client-driven process.  Once general goals 
have been identified, the therapist and client work together to reduce large goals into smaller, 
more manageable, and behaviorally-specific steps.  Pursuit and attainment of these goals are 
the driving force behind GRIP, and this goal-oriented focus is carried through to all phases of 
treatment.  Indeed, the pursuit of goals is a primary vehicle for promoting hope, optimism, 
and a focus on the future.  Ideally, therapy strives to help the client get “back on track” 
regarding his/her developmental trajectory and long-term aspirations (Hoffmann & Kupper, 
2002; McGorry, 1992, 2004; McGorry et al., 2003; Noordsy et al., 2002; Spaniol et al., 
2002). 
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 Medication adherence following resolution of an initial psychotic episode is critical to 
minimizing the potential for symptom exacerbation and relapse (Gitlin et al., 2001; 
Robinson, Woerner, Alvir, Bilder et al., 1999).  For clients who are already motivated to 
adhere to their prescribed medication regimen, behavioral tailoring (i.e., finding concrete 
ways to simplify one’s daily regimen and/or incorporate taking medication into one’s daily 
routine) will be used to further strengthen adherence and minimize the potential for missed 
doses.  Given the high rates of medication non-adherence following resolution of a first 
episode (e.g., Coldham et al., 2002), it is likely that many clients may not be keen on taking 
medication.  To address this, motivational interviewing will be employed.  Motivational 
interviewing explores a client’s ambivalence or resistance to taking medication, encourages 
consideration of the pros and cons of medication adherence, and highlights the potential 
benefits of taking medications with respect to achieving personally relevant goals (Miller & 
Rollnick, 2002).  Both behavioral tailoring and motivational techniques have received strong 
empirical support with respect to improving medication adherence among individuals with 
psychotic disorders (see reviews by Gray et al., 2002; Mueser et al., 2002; Zygmunt, Olfson, 
Boyer, & Mechanic, 2002). 
 The final objective of Phase 1 of GRIP is to develop a relapse prevention plan.  This 
is particularly important given the high risk of relapse following resolution of a first episode 
of psychosis (e.g., Gupta et al., 1997; McGlashan & Johannessen, 1996; Wiersma et al., 
1998).  Birchwood and colleagues (2000) have written extensively about relapse prevention 
in early psychosis, and delineate several key aspects of developing an effective plan.  First, it 
is important to identify a client’s “relapse signature.”  This corresponds to identifying those 
warning signs and symptoms that a client experienced prior to experiencing an acute 
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psychotic episode.  Common examples of early warning signs include increasing paranoia, 
difficulties concentrating, feeling depressed, anxious, or irritable, difficulty sleeping, social 
withdrawal, and/or neglecting personal hygiene.  It is also essential to identify any specific 
psychosocial triggers that may have precipitated a psychotic episode.  Following the 
identification of relevant warning signs and triggers, the client and therapist collaboratively 
develop a “relapse drill,” or action plan to respond to the onset of warning signs (Birchwood 
& Spencer, 2001).  This plan includes a variety of coping strategies that the client finds 
helpful (e.g., meditation, anxiolytic medication, positive self-statements) as well as the names 
and phone numbers of people to contact for help (e.g., case worker, therapist, physician).  
These steps will be followed for all GRIP clients in order to develop a personalized and 
comprehensive relapse prevention plan.  Relapse prevention efforts are part of best-practice 
recommendations in the management of first-episode psychosis (McGorry et al., 2003; 
Spencer et al., 2001).  Further, a recent randomized controlled trial demonstrated the utility 
of targeting early warning signs with cognitive and behavioral techniques in reducing relapse 
rates, as well as improving symptoms and overall functioning (Gumley et al., 2003). 
 Phase 2: Substance use.  All clients in GRIP receive two sessions of psychoeducation 
on the harmful effects of substance use on psychosis.  If the client has current substance use 
problems, he/she will receive up to eight additional sessions targeting this behavior.  Thus, 
the primary goals for this phase of treatment are: (1) educate the client about the dangerous 
effects of alcohol and drugs, (2) build motivation to reduce substance use (if applicable), and 
(3) teach the client skills for coping with high-risk situations involving substances (if 
applicable). 
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 At the beginning of this phase, therapists will assess a client’s current level of 
substance use and provide psychoeducation about the negative effects that substances can 
have on individuals recovering from a psychotic episode.  As in Phase 1, this process is 
interactive and client-driven, with the therapist supplementing or clarifying the client’s 
existing knowledge base.  The stress-vulnerability model is revisited, and substances are 
described as a primary mechanism of increasing one’s vulnerability to the re-emergence of 
symptoms and potential re-hospitalization (Elkins et al., 2004; Mueser & McGurk, 2004).  
Further, basic education regarding commonly used substances and their effects is provided 
(Mueser, Noordsy, Drake, & Fox, 2003). 
 Given the high rates of substance abuse among individuals with first episode 
psychosis, it is likely that many clients will have current substance use problems (Edwards et 
al., 2003).  To address this, the therapist will conduct a functional analysis of the client’s 
behavior in order to identify factors predisposing the client to use substances or factors 
maintaining this behavior.  In addition, therapists will employ motivational interviewing for 
clients who are resistant to reducing their substance use (Miller & Rollnick, 2002).  Indeed, 
substance use is emphasized as a barrier to recovery and an obstacle to the client achieving 
his/her personal objectives.  Goals identified in Phase 1 are utilized in this process and are 
used as support for the potential benefits of abstaining from substance use. 
 The final phase of this treatment module involves the therapist and client working 
together to develop a plan for maintaining abstinence (Bellack & DiClemente, 1999; Mueser 
et al., 2003).  A “behavioral action plan” lists specific substance use goals (e.g., abstain from 
alcohol), associated maintenance factors or reinforcers of the problematic behavior (e.g., 
anxiety reduction), and targeted strategies that the client can use to counteract these factors 
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without resorting to substances (e.g., meditation, exercise).  Related to this, clients will also 
develop a “substance use relapse prevention plan,” which lists high-risk situations for 
substance use (e.g., boredom, parties) and healthy coping strategies (e.g., contact a friend, 
read a book, assert desire to abstain when faced with peer pressure).  This plan will also 
contain contact information for people who can help the client when he/she is experiencing a 
craving to use substances.  Therapists will help clients tailor these plans to their specific 
needs, and will problem-solve regarding potential obstacles or difficulties with 
implementation. 
 A large component of the substance use treatment offered in GRIP is collaborative 
problem-solving and behavioral skills training (e.g., assertiveness).  This is consistent with 
recommended approaches for the psychosocial treatment of substance use disorders 
comorbid with psychosis (Bellack & DiClemente, 1999; Mueser et al., 2003).  Indeed, 
cognitive-behavioral treatment for substance use among individuals with psychotic disorders, 
including motivational strategies and skills training, has received strong empirical support 
(Barrowclough et al., 2001; Bellack & DiClemente, 1999; Drake et al., 2004; Mueser & 
Bond, 2000; Mueser et al., 2003). 
 Phase 3: Residual symptoms.  The primary goal of Phase 3 of GRIP is to reduce 
residual positive and negative symptoms that are distressing and/or impairing to the client.  
GRIP has separate modules for addressing: (1) delusions, (2) auditory hallucinations, and (3) 
negative symptoms. 
 CBT for psychotic symptoms has received increasing attention over the last 15 years, 
and several comprehensive treatment manuals have been written (Chadwick, Birchwood, & 
Trower, 1996; Fowler, Garety, & Kuipers, 1995; Kingdon & Turkington, 2004).  Most of the 
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work on CBT for psychosis has originated in the UK, and unfortunately there has not been as 
much widespread enthusiasm or dissemination in the United States thus far (Mueser & 
Noordsy, 2005).  Nevertheless, as will be discussed below, there is consistent evidence for 
the effectiveness of CBT in the treatment of residual psychotic symptoms (e.g., Gaudiano, 
2005). 
 CBT for psychosis is heavily rooted in psychological models of psychotic symptoms 
and therapeutic techniques are based on these formulations.  For example, researchers have 
postulated that delusions may result from a faulty reasoning style whereby individuals have a 
tendency to quickly “jump to conclusions” about anomalous experiences and have great 
difficulty generating alternative, more plausible explanations (Freeman et al., 2004; Garety & 
Freeman, 1999).  There is also evidence that persecutory delusions in particular may be based 
on maladaptive attributional styles in which other people are consistently blamed for negative 
events, and that this may represent attempts to protect a fragile self-concept (Kinderman & 
Bentall, 1996).  These theories suggest that treatment of delusions should strive to increase 
clients’ cognitive flexibility and encourage a more logical, facts-driven, empirical cognitive 
style, as well as address underlying self-esteem concerns (Barrowclough et al., 2003; Garety, 
Fowler, & Kuipers, 2000). 
 With respect to auditory hallucinations, there is evidence suggesting that voices are 
typically reflective of internal mental phenomena (i.e., automatic thoughts) misattributed to 
external sources, and that much of the subjective distress that clients experience appears to 
stem from their dysfunctional interpretations of the voices (e.g., as external phenomena that 
are malevolent; Bentall, Haddock, & Slade, 1994; Rector & Beck, 2001).  Therefore, based 
on techniques from traditional CBT, CBT for psychosis assists clients in modifying their 
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maladaptive beliefs about the nature of their voices, which ideally results in a more positive 
emotional response and greater sense of control (Garety et al., 2001; Kingdon & Turkington, 
2004).  Further, clients can be taught how to minimize exposure to environmental factors 
precipitating voices and/or to employ healthier coping strategies in response to voices 
(Tarrier et al., 1993). 
 Finally, negative symptoms are the least understood and most difficult residual 
symptoms to treat.  Behavioral approaches are often emphasized, particularly with respect to 
symptoms such as avolition or anergia.  Various clinical researchers assert that the 
consequences of negative symptoms (e.g., social withdrawal, inactivity) need to be targeted 
in treatment through techniques akin to “behavioral activation” in CBT for depression (Beck, 
1995; Falzer, Stayner, & Davidson, 2004; Turkington et al., 2004). 
 GRIP prescribes a variety of cognitive-behavioral techniques based on the work cited 
above.   Treatment of delusions employs three strategies: generating alternative explanations 
to a variety of situations, conducting behavioral experiments, and examining the internal 
consistency of beliefs (Chadwick et al., 1996; Fowler et al., 1995; Kingdon & Turkington, 
2004).  Clients are encouraged to increase their cognitive flexibility starting with less 
personal, non-emotionally- laden situations (e.g., generating many possible interpretations of 
a photograph), and then advancing to situations with more personal relevance.  This activity 
can be done in the office or in vivo, in outside settings that may activate the delusional belief 
system (e.g., paranoia activated around a group of people laughing).  Another strategy for 
addressing delusions involves conducting behavioral experiments, which are carefully 
orchestrated tests of one’s beliefs.  For example, if a client has a delusion that others can read 
his mind, a behavioral experiment may involve sitting in a public place and attempting to 
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mentally send a message to somebody, such as “look out, a brick is about to fall on you!”  If 
the target person does indeed look up within a specified amount of time, the client’s belief 
would be confirmed; if not, the belief would be disconfirmed.  In all behavioral experiments, 
clear experimental parameters and criteria need to be established a priori.  This can be a 
powerful method to help clients re-evaluate the validity of their beliefs, and therapists are 
encouraged to conduct such experiments outside of the therapy office to promote increased 
generalization.  Finally, a third method for addressing delusions is to help the client examine 
the internal consistency of his/her belief (i.e., reality-testing), which involves systematically 
examining the logic behind one’s belief, and determining the probabilities of individual 
components of the belief. 
 GRIP prescribes two primary strategies for addressing auditory hallucinations: coping 
strategy enhancement (Tarrier et al., 1993) and interpersonalizing voices (Chadwick et al., 
1996).  Coping strategy enhancement involves identifying the typical antecedents (e.g., 
stress, anxiety) and coping strategies for a client’s voices (e.g., yell back at voices), as well as 
the consequences of this behavior (e.g., public attention).  Clients are encouraged to consider 
the negative consequences of their current coping strategies and to work with the therapist to 
practice more adaptive coping strategies (both in-session and for homework).  They are also 
encouraged to avoid situations that increase the likelihood of experiencing voices (i.e., 
antecedents).  Another strategy for addressing auditory hallucinations involves 
interpersonalizing voices.  Clients are encouraged to respond to their voices the way they 
might respond to another person (e.g., by not yelling back) and to modify their perceptions of 
the voices in order to reduce distress.  A final way to address voices is through behavioral 
experiments.  For example, not complying with commands made by voices can be a powerful 
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test of the possible feared consequences; when clients emerge unharmed, they may begin to 
re-evaluate their beliefs in the voices’ omnipotence. 
 Finally, negative symptoms are addressed in GRIP through targeting the 
consequences of such symptoms, including low activity and social withdrawal (Falzer et al., 
2004).  Clients are asked to monitor times during the week when they are experiencing 
positive moods and note what they are doing.  They are then encouraged to increase 
participation in those activities, as a way of breaking the cycle of inactivity and limited 
reinforcement.  Indeed, the pursuit of personal goals is continuously encouraged as well, as is 
social re- integration (addressed more directly in the final phase of treatment). 
 Overall, CBT for psychosis has received considerable empirical support, and has been 
shown to be especially effective for reducing the frequency and severity of positive 
symptoms (see reviews by Birchwood, 1999; Dickerson, 2000; Garety et al., 2000; 
Gaudiano, 2005; Gould et al., 2001; Mueser et al., 2002; Pilling, Bebbington, Kuipers, 
Garety, Geddes, Orbach et al., 2002; Rector & Beck, 2001; Tarrier, 2005; Turkington et al., 
2004).  In meta-analytic reviews of the literature, CBT for psychosis has been associated with 
medium to large between-group effect sizes for post-treatment gains, ranging from .65-.91 
(Gould et al., 2001; Rector & Beck, 2001).  These gains tend to be maintained at follow-up.  
Further, stronger effects are seen for longer-term treatments, delivered over six months to a 
year (Garety et al., 2000; Pilling, Bebbington, Kuipers, Garety, Geddes, Orbach et al., 2002).  
Finally, most of the foregoing describes work done with chronically ill populations; however, 
as evident in the above review on psychosocial treatment for first episode psychosis, there is 
increasing use of CBT for psychotic symptoms in an early psychosis population, with 
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promising results (Haddock, Morrison, Hopkins, Lewis, & Tarrier, 1998; Lewis et al., 2002; 
Tarrier et al., 2004). 
 Phase 4: Functional recovery.  The foregoing has emphasized that a majority of 
individuals recovering from a first episode will experience a variety of functional deficits 
despite symptomatic reduction with antipsychotic medication, and that these deficits are 
associated with poor long-term outcome and increased risk for relapse and re-hospitalization 
(Birchwood et al., 1998; Erickson et al., 1989; Svedberg et al., 2001).  Thus, GRIP strives to 
facilitate functional recovery, and devotes Phase 4 to addressing several core functional 
deficits.  The key objectives of this phase are to improve: (1) social skills and social support, 
(2) role functioning, (3) recreational activity, and (4) self-esteem.  As with previous treatment 
phases, therapists have the flexibility to tailor GRIP to the client’s specific needs and 
concerns. 
 Social skills training (SST) is a large component of this treatment phase, and targets 
deficits in specific social behaviors, such as poor eye contact or inappropriate voice volume.  
More complex deficits such as poor conversational ability or difficulties with assertiveness 
are targeted as well (Bellack, Mueser, Gingerich, & Agresta, 1997).  SST is based on 
principles of modeling and operant conditioning, and generally consists of the following 
steps: (1) therapist identifies skill deficit(s), (2) therapist describes and models appropriate 
social behavior, (3) therapist and client role-play using relevant skill, (4) therapist provides 
feedback and positive reinforcement, (5) role-play is repeated, and (6) homework to practice 
the new skill is assigned.  This process is tailored to the specific needs of the individual 
client, and is conducted in a highly structured, systematic, and repetitive manner to maximize 
learning and retention.  Overall, SST for individuals with psychotic disorders has been shown 
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to be effective at teaching clients appropriate social skills, with associated increases in self-
efficacy and modest improvements in social functioning (Heinssen, Liberman, & 
Kopelowicz, 2000; Mueser & Bond, 2000; Penn & Mueser, 1996; for an exception, see 
Pilling, Bebbington, Kuipers, Garety, Geddes, Martindale et al., 2002, but see Mueser & 
Penn, 2004 for reaction to Pilling et al.). 
 In addition to deficits in social skills, clients may also lack adequate levels of social 
support.  Consistent with this, a powerful research finding is that clients with psychotic 
disorders tend to rank making new friends and other social concerns as their highest 
priorities, above symptomatic relief (Coursey, Keller, & Farrell, 1995).  Thus, barriers to 
social support will be identified and addressed in treatment.  For example, for clients with 
limited opportunities to meet others, therapists can assist with brainstorming about good 
places in which to meet new people (e.g., local coffee shop, gym) and develop homework 
assignments in which clients attempt to make new social connections.  Further, social skills 
training may be required if skills deficits represent primary obstacle s to obtaining social 
support.  This overall approach to building social support is a core component of illness-
management and recovery programs for patients with chronic schizophrenia (Mueser et al., 
2002). 
 As discussed above, clients recovering from an initial psychotic episode are often 
developmentally-stalled or off- track with respect to their peers.  In order to address this, 
GRIP therapists will liaise closely with outside agencies as well as members of clients’ 
treatment teams in order to help connect clients to appropriate services (e.g., supported 
employment).  Thus, in this capacity the therapist may assume a secondary role as a case 
manager.  In addition, therapists will work with clients on identifying and implementing 
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smaller tasks needed to achieve larger school- or work-related goals.  For example, for a 
client who wishes to return to college, the therapist may assist the client with filling out an 
application, selecting courses from a course catalogue, and/or preparing for specific classes. 
 To facilitate recreation and leisure activity, the therapist works with the client to 
identify specific hobbies or interests that he/she has previously enjoyed.  Alternatively, the 
therapist may ask the client to monitor times during the week when he/she is experiencing a 
positive mood and note what he/she is doing at the time.  (This general process is similar to 
strategies employed in the treatment of negative symptoms.)  Once a list of pleasurable 
activities has been compiled, clients are encouraged to engage in them for homework and to 
monitor their subjective experience. 
 Low self-esteem is pervasive in early psychosis and can interfere with social re-
integration and the pursuit of functional goals (Bassett et al., 2001).  To address this, GRIP 
prescribes an approach developed by Tarrier and colleagues in the UK, which aims to boost 
self-esteem by focusing attention on an individual’s positive qualities (Hall & Tarrier, 2003).  
The basic steps involved are as follows: (1) clients are asked to produce a list of positive 
qualities they possess and to rate how much they believe they possess those qualities, from 0-
100; (2) clients are then asked to provide specific and detailed behavioral examples of those 
qualities; (3) clients are then asked to re-rate how much they believe they possess those 
qualities.  It is expected that ratings will be higher after clients have had time to think of 
behavioral examples illustrating their positive attributes.  Therapists emphasize the fact that 
clients’ positive beliefs about themselves are strengthened by focusing attention on these 
attributes, rather than dwelling on the negative.  Thus, clients’ self-esteem increases, and they 
learn that they have the ability to improve their self-concept and mood through re-directing 
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their attention to these positive qualitie s.  Overall, preliminary data regarding the efficacy of 
this approach in boosting self-esteem has been promising (Hall & Tarrier, 2003).   
 Finally, the stigma of severe mental illness is pervasive, is likely to have a negative 
effect on self-esteem, and may serve as a barrier to functional recovery by inhibiting social 
re-integration (McGorry, 1992; Torrey, 1995).  GRIP prescribes several techniques that can 
be used to combat the effects of stigma.  Psychoeducation is critical in providing accurate 
information about mental illness and promoting the view that recovery can and does occur, 
contrary to some prevailing societal beliefs.  Strategies such as putting clients in contact with 
other clients who have recovered from severe mental illness, and/or discussing individuals 
that have succeeded in the face of adversity can instill hope and optimism in clients who may 
be feeling discouraged and disheartened.  Clients can be encouraged to be advocates for 
mental illness and educate friends and family members, which may be empowering for the 
client and enlightening for the audience.  Further, therapists can assist clients with evaluating 
the pros and cons of self-disclosing their illness to others, and can practice this process 
through in-session role-plays. 
 In summary, GRIP prescribes a variety of evidence-based clinical approaches, 
including cognitive-behavioral techniques, motivational interviewing, and psychoeducation, 
with the primary aims of removing key barriers to recovery (i.e., medication non-adherence, 
substance use, residual symptoms) and facilitating functional recovery and psychological 
adjustment following an initial episode of non-affective psychosis. 
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Overview of Current Study and Hypotheses 
 The current study consisted of the development and initial evaluation of GRIP with 
respect to variables such as feasibility and clinical utility.  There were two primary stages of 
the research: (1) manual development and (2) uncontrolled open trial. 
 In stage one, the preliminary GRIP manual was revised based on consultation with 
first episode researchers, clinicians, and consumers. 
 In stage two, an uncontrolled open trial of GRIP was conducted to evaluate clinical 
and psychosocial benefits, feasibility, tolerability, and qualitative therapist and client 
impressions of the treatment. 
 Primary hypotheses for the open trial of GRIP were as follows: 
(a)  GRIP will be associated with clinically significant improvements (i.e., within-group 
effects) with respect to the primary outcome of social functioning. 
(b) GRIP will be associated with improvements (i.e., within-group effects) with respect 
to the secondary outcomes of symptomatology, substance use, attitudes toward medication, 
and personal goal achievement. 
(c) GRIP will be well- tolerated, favorably received, and feasible to implement in an 
outpatient clinic (based on therapist and client report). 
 The ultimate aim of the open trial was to inform additional revisions to the manual 
and lay the groundwork for a randomized controlled trial of GRIP to provide a more stringent 
test of its efficacy.  This stepwise process is consistent with recent recommendations for the 
development of manualized treatments (Carroll & Nuro, 2002; Onken, Blaine, & Battjes, 
1997; Rounsaville, Carroll, & Onken, 2001).  Procedures for each stage of the current study 
are described in detail in the following section.
  
  
 
CHAPTER TWO 
METHOD 
 
GRIP Manual Development 
 The preliminary version of GRIP included recommended elements of standardized 
therapy manuals, includ ing theoretical background and rationale for treatment, an overview 
of treatment, specified goals and defining features of treatment, treatment logistics, and 
summaries/outlines for treatment sessions (Carroll & Nuro, 2002).  Further, GRIP was 
designed to address common critiques of manualized treatments, which include perceived 
underemphasis on non-specific factors and the therapeutic alliance, restrictions on clinical 
judgment and limited flexibility to tailor treatment based on clients’ needs, and exclusion of 
clients with comorbid conditions such as substance use (Addis, Wade, & Hatgis, 1999; 
Carroll & Nuro, 2002). 
 The first stage of the study consisted of further development and revision of the GRIP 
manual based on input from researchers, clinicians, and consumers.  Indeed, to bridge the gap 
between research and practice, it is recommended that clinicians and consumers be closely 
involved in the development of any new treatment (Addis et al., 1999; Dobson & Hamilton, 
2002; Onken et al., 1997; Rounsaville et al., 2001; Street, Niederehe, & Lebowitz, 2000; 
Westen, 2002).  The manual development team for GRIP consisted of the following 
researcher consultants: Jane Edwards, Ph.D. (Early Psychosis Prevention and Intervention 
Centre in Australia), Jean Addington, Ph.D. (Department of Psychiatry, University of 
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Toronto), and Alan Bellack, Ph.D. (Departments of Psychology and Psychiatry, University of 
Maryland).  All are internationally renowned experts in the areas of early psychosis and/or 
psychosocial treatment of schizophrenia.  Clinician consultants for GRIP included: Johanna 
Boobas, M.Ed., L.C.S.W. and Jennifer Nieri, L.C.S.W.  Both are clinical socia l workers in 
the UNC Department of Psychiatry who regularly see clients and are closely involved with 
ongoing research in the department.  Finally, the GRIP manual development team also 
consisted of three local consumer consultants (two men and one woman).  These individuals 
were high-functioning, clinically-stable outpatients who recently experienced an initial 
episode of psychosis.  All GRIP consultants were paid for their time and effort. 
 The preliminary version of GRIP was distributed to the consultants, who had one 
month to review and critique the manual.  They were provided with standardized rating 
forms that asked them to rate and comment on numerous aspects of GRIP, including manual 
organization, content, therapeutic techniques, clinical vignettes, handouts and worksheets, 
procedures for liaising with indigenous supporters, and overall user-friendliness.  Following 
the receipt of consultants’ completed rating forms, each participated in teleconferences or 
face-to-face meetings to further elaborate on his/her comments, and all recommendations 
were compiled and considered by the study investigators.  Consultant feedback was 
evaluated for common themes, and, in the case of contradictory suggestions, consensus 
agreement was reached through discussion with other GRIP investigators (e.g., Dr. Kim 
Mueser at Dartmouth Medical School).  Suggestions deemed impractical or of limited utility 
by the study investigators were not incorporated.  Based on this careful review of all 
consultant feedback, appropriate revisions were made to the GRIP manual, in preparation for 
the subsequent open trial. 
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Open Trial of GRIP 
Research Design and Overview 
 GRIP was evaluated in an uncontrolled, pre-post design and was offered as an adjunct 
to routine care (i.e., antipsychotic medication and case management) at the UNC Hospitals 
Schizophrenia Treatment and Evaluation Program (STEP) and the Outreach and Support 
Intervention Services (OASIS) Clinic, a specialized program for early psychosis.  This study 
was approved by the UNC Behavioral Institutional Review Board.  Each participant was 
offered up to 36 sessions of GRIP. 
At this stage of treatment development, it is recommended that only a few outcome 
variables be measured to assess preliminary efficacy (Rounsaville et al., 2001).  Thus, the 
primary clinical outcome in this study was social functioning, which is the key target of 
GRIP.  Secondary outcomes in this trial included symptoms, personal goal attainment, 
attitudes toward antipsychotic medication, and substance use.  In addition, qualitative 
impressions of GRIP were assessed via feedback forms completed by both participants and 
therapists. 
 Clinicians in this study included three clinical social workers from the UNC 
Department of Psychiatry, and two clinical psychology doctoral students at UNC.  The 
primary author of the GRIP manual (DLP; a licensed clinical psychologist) provided weekly 
supervision to all therapists.  All sessions were audiotaped and reviewed by DLP to aid in 
clinical supervision and monitoring of treatment fidelity. 
Participants 
 The sample was comprised of 10 individuals recovering from an initial psychotic 
episode.  Table 5 summarizes the sample’s demographic and clinical characteristics.  Specific 
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inclusion/exclusion criteria were as follows: (1) age 18 and over, (2) meets DSM-IV criteria 
for schizophrenia-spectrum disorder, (3) recovering from first episode of functional 
psychosis (i.e., individuals with organic brain disorder were excluded), (4) less than one year 
of treatment for psychosis, (5) clinically stable (i.e., outpatient for at least one month), (6) IQ 
> 70, (7) willing and able to provide informed consent, and (8) currently receiving routine 
care at UNC STEP or OASIS clinics.  Individuals with comorbid substance abuse were 
eligible for the study. 
Measures 
 Baseline diagnostic screen.  A diagnostic screen was conducted using the Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams, 
1996).  Raters were trained to conduct the SCID-I to a gold standard of inter-rater reliability 
(i.e., kappa > .80). 
 Demographic and clinical information.  The following information was obtained 
from participants via interview and chart review: date of birth, gender, race, marital status, 
level of educational attainment, approximate duration of untreated illness (i.e., from 
beginning of prodromal phase), approximate duration of untreated psychosis (i.e., from 
beginning of active psychosis), number of hospitalizations, and current medications.  
Social functioning.  The primary measure of social functioning was the Social 
Functioning Scale (SFS; Birchwood, Smith, Cochrane, Wetton, & Copestake, 1990), a 79-
item self-report questionnaire designed to assess social and occupational functioning among 
outpatients with schizophrenia.  In this study, the SFS was administered in an interview-
based format to ensure that all questions were understood and answered by participants.  
Items are rated on Likert-type and frequency scales, and self-report ratings can be 
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supplemented with information from collateral sources (e.g., an indigenous supporter).  The 
SFS assesses seven domains of social functioning: social engagement (e.g., how often do you 
start a conversation at home?), interpersonal behavior (e.g., how often are you able to carry 
out a sensible or rational conversation?), prosocial activities (e.g., how often do you go to a 
coffee shop?), recreation (e.g., hobbies), independence-competence (e.g., ability to do 
laundry), independence-performance (e.g., frequency of grocery shopping), and 
employment/occupational status.  Sub-scale scores are produced for each of these domains 
and a total score is computed by summing all items.  Factor analysis has demonstrated that a 
single factor accounts for over 50% of the variance in scores, and sub-scale scores are highly 
intercorrelated.  Therefore, Birchwood et al. recommend using the total score as an overall 
index of psychosocial functioning.  In this study, the SFS total score served as a primary 
outcome variable. 
 The SFS has demonstrated good internal reliability (a = .80 for total score).  Further, 
there is high concordance between ratings made by patients and informants, with good inter-
rater reliability (r = .94) and a large rater/self-report correlation (r = .78) (Birchwood et al., 
1990; Dickerson, Ringel, & Parente, 1997).  Construct and criterion-related validity as well 
as sensitivity of the SFS have been established through factor analysis and studies of patients, 
relatives, and community samples (Birchwood et al., 1990). 
 To supplement information from the SFS, the Multidimensional Scale of Perceived 
Social Support (MSPSS; Zimet, Powell, Farley, Werkman, & Berkoff, 1990) was 
administered.  The MSPSS is a 12- item self- report questionnaire assessing the perceived 
adequacy of support from family, friends, and significant others.  Items are rated on 5-point 
Likert scales and a total score is obtained by summing items.  The MSPSS has demonstrated 
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good psychometric properties across multiple stud ies.  Internal reliability is good (a = .84-
.92) and test-retest reliability is adequate (r = .72-.85).  Construct validity has been 
established through factor analysis and studies of college undergraduates, younger 
adolescents, pregnant women, and medical residents. 
Symptomatology.  Symptoms were assessed with the Positive and Negative Syndrome 
Scale (PANSS; Kay, Opler, & Fiszbein, 1992).  The PANSS is a widely used, semi-
structured clinical interview designed to assess the severity of positive, negative, mood, and 
behavioral symptoms over the past week.  On the basis of data gathered from the interview, 
ratings are made on 30 items using 7-point Likert scales, anchored by 1 (absent) to 7 
(extreme).  Four scaled scores are produced: Positive Symptoms, Negative Symptoms, 
General Psychopathology, and Total Score.  In this study, raters were trained to conduct the 
PANSS to a gold standard of inter-rater reliability (i.e., intraclass correlation [ICC] > .80). 
To supplement the PANSS, the Calgary Depression Scale for Schizophrenia (CDSS; 
Addington, Addington, & Maticka-Tyndale, 1993) was used to obtain a more sensitive 
measurement of depressive symptomatology among participants.  The CDSS is a nine item 
semi-structured interview-based scale which was developed for use specifically with 
individuals with psychotic disorders. 
 Substance use.  Alcohol and illicit drug use was assessed with the Alcohol Use Scale 
(AUS) and Drug Use Scale (DUS), respectively (Drake, Mueser, & McHugo, 1996).  The 
AUS and DUS were developed to assess and track substance use among individuals with 
severe mental illness.  On each scale, individuals receive a rating of 1-5, corresponding with 
diagnostic criteria for abstinence, use without impairment, abuse, dependence, or dependence 
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with institutiona lization.  Ratings are based on client self- report, clinician observation, and 
information from collateral sources (e.g., an indigenous supporter). 
 The AUS and DUS have demonstrated good psychometric properties (Drake et al., 
1996).  In longitudinal studies of individuals with severe mental illness living in the 
community, test-retest reliability for both scales has been excellent (i.e., close to 100%), and 
inter-rater reliability has also been good (kappa = .80-.95).  Both scales have been shown to 
be valid instruments as well, with high ratings of sensitivity (e.g., 94.7%) and specificity 
(e.g., 100%). 
 Attitudes toward medication.  The Brief Evaluation of Medication Influences and 
Beliefs (BEMIB; Dolder et al., 2004) was used to measure participants’ attitudes toward 
antipsychotic medication.  The BEMIB has been shown to reliably and accurately identify 
patients who are likely to be non-adherent with prescribed medication. 
Personal goal attainment.  A brief measure was developed in order to allow 
participants and therapists to rate progress toward goals in this study.  Each goal is evaluated 
on a five point Likert-type scale, reflecting the degree to which the participant or therapist 
believes that progress has been made over the course of treatment.  A rating of “5” indicates 
that the goal has been achieved, and a rating of “1” indicates that no progress has been made.  
 Qualitative feedback.  Qualitative impressions of GRIP were ascertained via brief 
questionnaires (with Likert-type rating scales) administered to both therapists and 
participants following completion of the program.  In addition, post-treatment interviews 
with participants (approximately 30 minutes) were conducted in order to gather more detailed 
qualitative feedback about the GRIP program.   
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 Feasibility and Tolerability.  The feasibility of administering GRIP was evaluated on 
the basis of information obtained from therapists during the course of weekly supervision.  
The tolerability of GRIP was evaluated through examination of participants’ attendance 
records as well as computation of early treatment termination rates (i.e., for clients who 
terminated before 12 sessions; see below for definition of treatment completion). 
Procedure 
Participants were referred to the study by their primary treating clinicians in either the 
UNC STEP or OASIS Clinics.  Once participants completed the informed consent process, 
they were screened for the presence of a non-affective psychotic disorder using the SCID-I. 
Once a diagnosis of non-affective psychosis was confirmed (and other relevant 
inclusion criteria were satisfied), research assistants assessed participants on the PANSS, 
CDSS, AUS/DUS, SFS, MSPSS, and BEMIB.  Participants received $30 for completing the 
baseline assessment. 
Following the baseline assessment, participants were offered up to 36 sessions of 
GRIP.  After 12 sessions of GRIP, clients and therapists assessed progress regarding personal 
goal achievement, and discussed whether to continue with treatment.  This decision was 
collaborative, and depended on several factors, including: goal achievement, client’s clinical 
status, client’s interest/investment in additional treatment, and the therapist’s clinical 
judgment.  All clients were invited to continue with the rest of the program; however, for 
clients who possessed limited motivation to continue, and/or who had achieved all of their 
initial therapy goals, this served as a natural termination point.  Given that the first 12 
sessions of GRIP cover critical illness management and psychoeducational content, they 
were deemed the “minimum effective dose” of the program.  Thus, clients who completed 12 
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or more sessions of GRIP were identified as “treatment completers,” while clients who 
completed fewer than 12 sessions were identified as “treatment non-completers.” 
To ensure fidelity to the manual, Dr. David Penn listened to audiotapes of all sessions 
and provided weekly supervision to study therapists.  A formal GRIP fidelity rating scale and 
coding manual was developed in concert with the open trial.  This rating scale was based on 
the project investigators’ clinical and research experience, as well as currently available 
fidelity scales for psychosocial treatments for psychotic and non-psychotic disorders 
(Baucom, 2005; Haddock et al., 2001; Penn & Perkins, 2005; Startup, Jackson, & Pearce, 
2002).  The final GRIP fidelity scale (see Appendix; Waldheter, Penn, & Mueser, 2007) 
provides an opportunity for coders to rate therapists’ adherence to the manual as well as the 
overall quality of therapeutic intervention (i.e., competence).1 
 Baseline assessment procedures were repeated for post-test assessment, in which 
participants were assessed on the PANSS, CDSS, AUS/DUS, SFS, MSPSS, and BEMIB.  
For treatment non-completers, post-test assessment took place at 12 weeks following their 
first session.  For treatment completers, post-test assessment took place immediately 
following treatment termination.  All participants and therapists completed the goal 
attainment form, as well as qualitative feedback questionnaires.  Finally, participants were 
asked about their experiences in therapy during a post-treatment interview (which was 
audiotaped).  Participants received $30 for completing the post-test assessment. 
                                                 
1 The GRIP fidelity scale was completed towards the end of the open trial, and thus was not formally utilized to 
monitor fidelity for this phase of the project.  It currently is being used in the randomized controlled trial of 
GRIP being conducted at the OASIS program.  Consistent with standards used in treatment outcome research 
(D. Baucom, personal communication, April 4, 2005), 25% of all sessions are being coded for adherence and 
competence. 
  
  
 
CHAPTER THREE 
RESULTS 
 
Manual Development 
Briefly, highlights of the extensive manual revisions made as a result of this process 
include: (1) increased emphasis on risk assessment and prevention of suicidality (particularly 
emphasized by researcher consultants), (2) detailed guidelines for ongoing treatment of 
substance use and medication non-adherence (based primarily on discussions with Drs. 
Bellack and Mueser), (3) expanded coverage of motivational interviewing techniques (based 
primarily on discussions with clinician consultants), (4) emphasis on flexible treatment 
duration and guidelines for assessing progress (based on discussions with Dr. Addington), (5) 
guidelines for prioritizing and addressing multiple problems (e.g., persistent symptoms or 
functional deficits; based on discussions with clinician consultants), (6) addition of 
troubleshooting section and glossary of core therapeutic techniques (based on discussions 
with researcher and clinician consultants), and (7) re-designed handouts and worksheets 
(based on discussions with consumer and researcher consultants).  Please see Table 6 for a 
summary of all revisions made to the treatment manual during this phase of the study. 
Open Trial 
Overview of Data Analyses 
 Given the small sample size of this study, formal inferential statistics were not 
appropriate.  Rather, we calculated within-group effect sizes for continuous outcome 
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variables in order to evaluate the magnitude of pre-post change in our key clinical domains, 
including social functioning and social support (SFS, MSPSS), symptoms (PANSS, CDSS), 
and attitudes toward medication (BEMIB).   Effect sizes were calculated in two ways: the 
conventional method examining pre-post change correcting for the pre-test standard 
deviation (Cohen, 1988), and an alternative method that accounts for the correlation between 
pre- and post-test values (Dunlap, Cortina, Vaslow, & Burke, 1996).  Both methods generate 
a Cohen’s d value that can be evaluated according to the following criteria : small (d = .20), 
medium (d = .50), and large (d = .80).  Dunlap and colleagues recommend the use of the 
alternative method because it typically results in a more conservative estimate of within-
group change (i.e., “corrected Cohen’s d”); however, they acknowledge that there is no 
universally agreed upon method of calculating such parameters.  Both effect size estimates 
are reported below for each of our outcome variables. 
We also determined the proportion of participants who experienced a “clinically 
significant change” in their social functioning (i.e., SFS total score) and in psychotic and 
general symptoms (i.e., PANSS scores).  Indeed, in this study, social functioning was the key 
target of our intervention (and thus the primary outcome variable), and psychotic symptoms 
were a critical secondary outcome (from both a clinical and empirical perspective, as 
symptoms are the most frequently reported outcome in other first-episode studies; e.g., Penn 
et al., 2005).  Clinically significant change on the SFS was determined using criteria by 
Jacobson and Truax (1991), which currently is the most commonly used method of 
calculating clinical significance (McGlinchey, Atkins, & Jacobson, 2002).  Further, 
McGlinchey and colleagues (2002), in a study comparing various methods of calculating 
clinical significance, stated that “the evidence of this study supports the [Jacobson and 
  
  
67 
Truax] method as a ‘null’ method that has yet to be rejected by an alternative method of 
superior performance” (p. 542).  Clinically significant change on the PANSS was evaluated 
according to criteria typically used in schizophrenia research (e.g., 20% reduction in 
symptoms; Cather et al., 2005; Kane, Honigfeld, Singer, & Meltzer, 1988; Leucht et al., 
2005). 
To evaluate change in substance use, we examined individual changes from pre-test 
to post-test with respect to substance abuse or dependence on the AUS/DUS.  In addition, we 
evaluated the level of personal goal attainment reported by participants and therapists at post-
test on standardized measures.  Finally, we reviewed qualitative feedback from participants 
and therapists about GRIP (i.e., on questionnaires and in audiotaped interviews).  Transcripts 
of audiotaped interviews with participants were examined for common themes; these 
findings are summarized below. 
Treatment engagement  and baseline group differences between treatment completers and 
non-completers 
One participant disengaged from all treatment services after 1 session of GRIP (due 
to exacerbation of psychotic symptoms); thus, pre-post data are available for 9 of 10 
participants enrolled in the study. 2  Of these 9 individuals, 6 were “treatment completers” 
(i.e., completed at least 12 sessions) and 3 were “treatment non-completers” (i.e., completed 
fewer than 12 sessions).  Therapists and clients provided the following reasons for early 
treatment discontinuation: difficulty balancing multiple treatment providers (e.g., 
psychiatrist, case manager, GRIP therapist) (n = 1), weekly time commitment and lack of 
                                                 
2 To account for this early study dropout, both “intent-to-treat” and “last observation carried forward” methods 
of analysis were considered.   Given clinical/theoretical and statistical/empirical considerations (Lachin, 2000;  
Patterson et al., 2006), however, we decided to exclude this individual from analyses altogether. 
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motivation (n = 1), and paranoia regarding the treatment team and perception that therapy 
was not beneficial (n = 1). 
Visual inspection and a 1-way analysis of variance (ANOVA) regarding baseline 
clinical and demographic data revealed several key (yet primarily non-significant) 
differences between completers and non-completers (see Table 7 for a summary).  Briefly, 
non-completers were younger, had been ill for longer, reported more social dysfunction, 
perceived less social support (p < .05), and were more symptomatic than treatment 
completers at baseline.  (Given the very small sample size, however, these analyses are more 
descriptive and hypothesis-generating, than conclusive.) 
Finally, the mean number of sessions attended for the overall sample was 15.1 (SD = 
10.6; range = 4-33).  The mean number of sessions for completers was 20.2 (SD = 9.4; range 
= 12-33) and 5.0 (SD = 1.0; range = 4-6) for non-completers. 
Clinical Outcomes 
 Within-group effect sizes for continuous variables.  Table 8 provides pre-post means 
and standard deviations for the following measures: SFS, PANSS, MSPSS, CDSS, and 
BEMIB.  A review of Table 9 reveals that, for all participants, small positive within-group 
effect sizes were observed for most measures, except for a large positive effect size observed 
for PANSS positive symptom scores (p < .05) and small negative effect sizes for MSPSS and 
BEMIB scores.  This pattern of findings is essentially unchanged when corrected Cohen’s d 
values are considered.  Overall, these data indicate a small degree of improvement across 
most clinical domains when the total sample is considered. 
 An examination of outcomes for treatment completers vs. non-completers, however, 
may provide more meaningful information on the potential efficacy of GRIP (see Table 9).  
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On average, treatment completers demonstrated improvements on most measures, with a 
range of positive effect sizes from small (PANSS negative, CDSS, BEMIB), to medium (SFS 
total, PANSS general, total), to large (PANSS positive).  Slight deterioration was observed 
on the MSPSS.  For treatment non-completers, deterioration was observed in most domains, 
with a range of negative effect sizes from small (MSPSS), to medium (SFS total, PANSS 
total), to large (PANSS negative, general, BEMIB).  Improvement was observed on PANSS 
positive and CDSS scores (i.e., small and medium effect sizes, respectively).  It should be 
noted that a smaller degree of deterioration among non-completers was observed on several 
outcomes when considering the corrected Cohen’s d estimates; these differences were 
particularly salient for PANSS negative and general scores. 
 Clinically significant change.  Based on criteria from Jacobson and Truax (1991), one 
participant achieved a clinically significant improvement on the SFS total score.  That is, this 
individual (a treatment completer) demonstrated a “clinically reliable change” (i.e., improved 
to a greater degree than might be expected due to measurement error alone) and placed 
himself slightly above the normative group mean (i.e., 112) at post-test.  Indeed, this 
individual had a total score of 77 at pre-test and 113 at post-test, clearly demonstrating a 
significant degree of improvement.  This is consistent with clinical observations of his post-
test status, in which he had moved out of his mother’s house, was living successfully among 
peers in a group home, and was complying with a structured routine. 
 It should be noted that our sample’s pre-test mean on the SFS total score (i.e., 116) 
was greater than the normative group mean from Birchwood et al. (1990; i.e., 112), thus 
rendering the application of the Jacobson and Truax (1991) criteria difficult, since those 
criteria assume a pre-test level of functioning below a normative level.  This may likely be 
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due to cohort effects, as our sample (i.e., college-aged individuals from a high SES/highly 
educated region of the U.S.) differed significantly from the normative sample used by 
Birchwood et al. (1990) in the development of the SFS (i.e., middle-aged individuals from a 
lower SES/industrial area of Great Britain).  Despite these methodological limitations, visual 
inspection of pre-post change on the SFS total score in our sample revealed that two 
additional treatment completers demonstrated improvements of approximately 20 points 
from pre-test to post-test.  While not statistically defensible, it is likely that these changes 
were clinically meaningful for these individuals. 
 Examination of Table 10 reveals that three treatment completers (50% of that sub-
sample) achieved clinically significant improvements on the PANSS positive and negative 
subscales (i.e., at least a 20% reduction in scores).  One non-completer (33% of that sub-
sample) achieved this level of improvement in positive symptoms, and none of the non-
completers achieved a clinically meaningful reduction in negative symptoms.  Moreover, one 
treatment completer achieved a 50% reduction in positive and negative symptom scores; 
none of the non-completers demonstrated this magnitude of change. 
Finally, two treatment completers (33% of that sub-sample) demonstrated a clinically 
significant reduction in their general and total scores on the PANSS; none of the non-
completers demonstrated the same magnitude of improvement on these scales. 
 Substance use.  With respect to AUS/DUS scores, very little substance use was 
reported in our sample.  Nevertheless, one participant (a non-completer) who reported 
cannabis abuse at baseline was rated as abstinent following treatment. 
Personal goal attainment.  Fifty-eight percent of personal goals were collectively 
rated by participants at post-test as “very close to being achieved” or “achieved.”  When data 
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are examined based on treatment completion status, a more striking difference is evident.  
Indeed, while treatment completers collectively rated 68% of their personal goals at post-test 
as “very close to being achieved” or “achieved,” none of the treatment non-completers’ goals 
received those same ratings.  Examples of goals that completers achieved during 
participation in GRIP include: returning to school, making new friends, taking medication 
daily, and learning more about mental illness. 
 Therapists agreed with participants’ self-assessments of their goals, rating 52% of all 
goals as “very close to being achieved” or “achieved” at post-test.  Therapists rated 64% of 
treatment completers’ goals as “very close to being achieved” or “achieved,” while none of 
treatment non-completers’ goals received those same ratings. 
Qualitative Feedback 
 Overall, both participants and therapists reported favorable impressions of GRIP via 
questionnaires (see Table 11) and post-treatment interviews. 
Participants.  With respect to participant feedback on end-of-study questionnaires, 
positive ratings were obtained on the majority of items, particularly among treatment 
completers.  Indeed, these individuals provided high ratings on all items assessing variables 
such as the perceived utility of GRIP and its components, clarity of treatment materials, and 
the overall quality of treatment received.  While treatment non-completers provided positive 
ratings on items pertaining to treatment materials (e.g., information provided in GRIP, user-
friendliness), they reported less favorable impressions with respect to perceived 
utility/efficacy and quality of the program. 
 Post-treatment interviews with participants yielded richer information regarding the 
subjective experience of going through the GRIP program.  The majority of clients reported 
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that the most beneficial components of therapy were the social support from their therapist 
and the ongoing focus on goals.  For example, one client remarked, “My favorite part was 
having a person to talk to, a person that understands you, that knows what you’ve been 
through.”  Another client stated that, “[therapy is] like somebody holding your hand through 
a very bad dream.”  With respect to goals, one client stated, “[the most helpful part was] the 
fact that we spent time focusing on where I was at and talking about where I wanted to be 
and what kinds of things stood in the way.”  Another client remarked that, “[goal-setting] 
really did help me to get back to normal…[and it was] nice to have some goals and to see 
that you are making progress.”  Several clients also expressed an appreciation for the focus 
on education and relapse prevention in GRIP.  One client emphasized that “[GRIP] made me 
more conscious [about] when I have the psychosis episode, what do I do, what do I do 
wrong, how can I improve the situation, [and] how can I do it better for the next time.”  Other 
clients discussed the importance of identifying “red flags” as a means of avoiding a relapse.  
With respect to psychoeducation, one client asserted that “being educated about what you are 
going through is much better than living with a stigma.” 
 Most clients acknowledged that participation in GRIP positively impacted their 
recovery from psychosis and would recommend GRIP to peers going through similar 
experiences.  One client remarked, “it might just be me getting over it, but I can tell a 
difference of how I am now to how I was back at [the beginning of treatment].”  Another 
client acknowledged the general benefits of psychotherapy by stating, “I had never had 
therapy, so introducing me to therapy and teaching me how to open up to a therapist was very 
beneficial.” 
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 Finally, treatment non-completers were asked to elaborate on their reasons for 
terminating early.  Three primary reasons emerged in post-treatment interviews: (1) the time 
commitment of weekly therapy (a concern shared by completers) and/or the burden of 
multiple treatment providers and appointments, (2) a subjective sense of improvement and/or 
lack of appreciation for the benefits of continued treatment, and (3) persecutory ideation 
regarding the treatment team.  For example, one client remarked, “What kind of got to me a 
little bit was having [sessions] once a week…I would change it to once every two weeks.”   
This same client also stated that he wasn’t “being helped in achieving [his] goals” and that 
his “concerns were not adequately addressed.”  Another client claimed that he was feeling 
better and did not need additional treatment.  Further, this same client expressed 
dissatisfaction with the emphasis on goals by stating, “It helped just talking about my 
problems…but when it started getting to the goal stage I wasn’t really feeling it because I’m 
not really into setting goals.”  Finally, a third client was reluctant to report on reasons for 
dropout; however, her therapist acknowledged that the presence of residual paranoia was 
interfering with the client’s ability to trust and engage with her treatment team. 
Therapists.  With respect to therapist feedback on end-of-study questionnaires, 
positive ratings were obtained on most items, including those assessing the perceived utility 
of the treatment manual and materials.  In addition, most therapists stated that they would 
“highly recommend” the GRIP program to other practitioners.  Slightly lower scores were 
obtained on two items assessing the utility of GRIP for assisting specific clients with their 
symptoms and recovery; however, most therapists reported that GRIP was at least 
“somewhat helpful” in these areas (see Table 11).   
  
  
  
CHAPTER FOUR 
DISCUSSION 
 
Following a treatment conceptualization and development phase, an initial evaluation 
of the GRIP program has been promising.  It was hypothesized that GRIP would be 
associated with improvements in social functioning, social support, symptoms, substance use, 
and attitudes toward medication.  It also was hypothesized that GRIP would be feasible to 
implement in an outpatient setting, would be well-tolerated by clients, and would be well-
received by clients and therapists alike.  Our hypotheses were largely supported, 
notwithstanding a few caveats; findings are discussed in more detail below. 
Our open trial data indicate that, among participants who attended at least 12 sessions 
of treatment (i.e., completers), GRIP was associated with improvements in almost all 
measured domains, especially social functioning, positive and general symptoms, and goal 
attainment.  In contrast, early treatment termination (i.e., before 12 sessions) was associated 
with deterioration in almost all domains, particularly social functioning, negative and general 
symptoms, perceived social support, and attitudes toward medication.  Moreover, several 
treatment completers demonstrated clinically significant improvements in symptoms (i.e., 
positive, negative, general) and one completer demonstrated clinically significant 
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improvement in social functioning (as strictly defined by Jacobson & Truax, 1991); this same 
pattern of results was not true of treatment non-completers.3 
It should be noted that treatment non-completers demonstrated improvements in 
positive and depressive symptoms over the course of the study.  A reduction in these 
symptom domains over time, however, is expected in most individuals recovering from an 
initial psychotic episode (Addington et al., 1998; Tohen et al., 2000; Whitehorn et al., 2002).  
These findings, therefore, are consistent with the expected illness course in early psychosis.  
The improvement in positive symptoms among completers (described above) is also 
consistent with this expected finding; however, completers demonstrated a larger magnitude 
of improvement than non-completers in this domain (i.e., large vs. small effect size).  With 
respect to improvement in depression, it appears that both groups experienced a comparable 
reduction in symptoms.  Indeed, it is possible that the active and goal-directed approach of 
GRIP therapists facilitated a generalized behavioral activation among clients, with 
concomitant reduction in depressive symptoms (e.g., Beck, 1995).4 
Overall, while these outcome data must be interpreted with great caution, findings 
may support a dose-response effect for GRIP, with longer duration of treatment facilitating 
greater clinical improvements (and/or minimizing deterioration).  This would be consistent 
with findings from studies of therapy for a range of non-psychotic disorders (Westen, 
Novotny, & Thompson-Brenner, 2004).  Moreover, post-hoc analyses lent additional support 
                                                 
3 As discussed above, it is likely that additional treatment completers experienced clinically meaningful 
improvements in their social functioning; however, unique characteristics of our cohort precluded the 
application of the Jacobson and Truax (1991) criteria in most cases. 
 
4 Surprisingly, the effect size for this improvement is about twice as large in non-completers (i.e., medium vs. 
small effect).  A more fine-grained analysis of the data indicates that this is likely a statistical artifact stemming 
from a larger pre-test standard deviation in the completer distribution, which would serve to reduce the resultant 
effect size for that group on the CDSS. 
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to this hypothesis.  Indeed, change scores for all continuous variables in the study were 
positively correlated with the number of sessions attended (r = .4 -.7). 
 Completers and non-completers displayed several differences in their clinical 
presentations at the beginning of the study.  Post-hoc examination of their data revealed that 
non-completers reported less social support, more general psychiatric symptoms, and less 
social engagement than study completers at baseline.  In addition, they were younger and 
tended to be ill for longer periods of time than completers.  These baseline differences in our 
sample may shed light on potential predictors of early treatment termination and/or poor 
treatment response.  Indeed, there is evidence demonstrating that individuals with 
schizophrenia with greater social dysfunction and lower levels of activity are less likely to 
form a strong therapeutic alliance (Couture et al., 2006), and thus may benefit less from 
psychosocial intervention.  In addition, poor social functioning, younger age of illness onset, 
and longer periods of untreated illness are all poor prognostic factors in psychotic disorders 
(Birchwood et al., 1998; Malla, Norman, Manchanda, Ahmed et al., 2002; Mueser & 
McGurk, 2004).  Therefore, it is possible that the non-completers represented a more ill and 
potentially treatment-resistant subgroup of our sample. 
The overall sample demonstrated some deterioration with respect to perceived social 
support, which was an unexpected finding, given the focus on social support in GRIP.  One 
possible interpretation is that the provision of treatment may have been associated with 
increased insight and awareness of reduced social networks (Mintz et al., 2004).  
Alternatively, termination in treatment may have resulted in the experience of an important 
member of the clients’ social network (i.e., the therapist) leaving their lives.  A decrease in 
perceived social support was greater among treatment non-completers, however, which is 
  
  
77 
consistent with expectations and the aforementioned baseline group differences.  That is, 
these individuals were more likely to resist therapeutic engagement and were more likely to 
be experiencing greater levels of general social dysfunction. 
In addition to our promising quantitative results, qualitative feedback on the GRIP 
program from both therapists and clients was generally favorable.  Most of the study 
therapists stated that they would highly recommend GRIP to other clinicians working with 
first-episode clients.  Most participants, especially treatment completers, provided positive 
ratings of GRIP on feedback questionnaires.  During interactions with study investigators, 
participants reported that they particularly appreciated the support provided by their 
therapists, an opportunity to process the experience of their illness, as well as the focus on 
goals and educational information provided in GRIP.  One participant remarked, “It’s the 
only time I get to converse about what’s going on with my diagnosis and life.”  Thus, with 
respect to treatment needs, our data suggest that clients recovering from a first episode of 
psychosis are primarily concerned with receiving social support and a safe space in which to 
process this upsetting and confusing new experience, in addition to information and 
assistance with moving forward in their recovery (reflecting a combination of non-specific 
and specific factors).  
The primary objective of a small open trial is to evaluate the feasibility and 
tolerability of a new intervention (Mueser & Drake, 2005; Rounsaville et al., 2001).  Our 
findings with respect to these variables are somewhat mixed.  The average dose of treatment 
in our study (i.e., 15 sessions) was slightly higher than that provided in other small-scale 
trials of individual CBT for early psychosis (e.g., 10-11 sessions; Haddock et al., 1999; 
Jolley et al., 2003).  Overall treatment retention, however, was somewhat lower than 
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expected, with only 67% of participants enrolled in the study completing treatment (not 
including the individual who attended one therapy session and subsequently withdrew from 
all treatment services); thus, 33% of participants terminated prematurely.  While our 
retention rate is comparable to that of other studies in this area (e.g., 60-80%; Jackson et al., 
1998; Lewis et al., 2002; Power et al., 2003), Mueser and Drake (2005) advise that dropout 
rates over 30% are problematic and suggest the need for additional measures to improve 
retention in treatment. 
A review of our data suggests two primary factors influencing early treatment 
discontinuation in our sample: logistical (e.g., difficulties with weekly time commitment, 
balancing several treatment providers) and clinical (e.g., active psychosis, poor insight and 
appreciation for relevance of treatment).  Both therapist and client feedback were consistent 
in this regard.  In addition, anecdotal reports by study therapists suggest that the presentation 
of more structured, didactic material early in treatment may have adversely impacted some 
clients’ desire to remain in treatment.  Indeed, this information is critical data to gather in the 
treatment development process, and has been invaluable in informing necessary 
modifications to our protocol (described below).  Further, our findings appear to reflect the 
general difficulties of engaging and retaining young people with early psychosis in treatment 
(EPPIC, 2001; Jackson, McGorry, & Edwards, 2001; Judge et al., 2005). 
 Thus, preliminary results suggest that GRIP may be associated with clinical benefits, 
can assist clients in pursuing their personal goals, and is generally well-received by clients 
and therapists.  However, the small sample size, as well as the uncontrolled study design of 
the open trial, significantly limit the conclusions that can be drawn at this time, and preclude 
any causal inferences about the efficacy of GRIP.  In addition, it is possible that demand 
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effects contributed to the positive qualitative feedback we received from both participants 
and therapists.  Finally, the differential outcomes between completers and non-completers in 
the open trial underscore the importance of improving retention in therapy. 
These study limitations are being addressed in a randomized controlled trial (RCT) of 
GRIP, which is currently in progress at the UNC OASIS Clinic.  This study is randomly 
assigning 40 clients in the early stages of a psychotic disorder to one of two conditions: 
“treatment as usual” (i.e., medication and case management) or “GRIP + treatment as usual.”  
A variety of outcomes are being assessed, including social functioning, symptoms, substance 
use, recovery-oriented attitudes, goal attainment, and relapse/re-hospitalization.  Based on 
lessons learned from our open trial, several modifications have been made in an effort to 
increase engagement, minimize treatment dropouts, and improve outcomes.  GRIP therapists 
in the RCT are “keyworkers” at the OASIS Clinic, who also provide case management and 
serve as primary treatment contacts for all clients.  This will ideally streamline the process of 
treatment for clients, who are often faced with the challenge of balancing multiple providers 
and services.  In addition, GRIP is now being offered in a more flexible format (e.g., option 
of weekly or biweekly sessions) and therapists are able to meet with clients in the community 
(e.g., in clients’ homes).  This assertive outreach approach is frequently used in case 
management with first-episode clients (e.g., EPPIC, 2001), and we have now incorporated 
this perspective into the delivery of GRIP. 
In consultation with study therapists, we have begun to make additional modifications 
to the treatment manual in order to better address the needs of first-episode clients.  For 
example, a module on the psychological impact of a first episode, along with concomitant 
issues of grief and loss, has been added to Phase One of the treatment.  In addition, some of 
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the structured, didactic material that was presented early on in the treatment has been pushed 
back in order to allow clients more unstructured time initially to tell their stories and process 
their experience. 
Finally, consistent with the broader psychotherapy literature, a critical finding from 
our open trial is that clients recovering from an initial episode of psychosis are typically 
preoccupied with social/vocational issues and more general psychological concerns (e.g., 
“How has my future changed?” or “How will others react to me now?”), rather than 
psychotic symptoms alone.  That is, residual psychotic symptoms are often not a primary 
concern for clients, although they have traditionally been the focus of treatment for psychotic 
disorders (Coursey et al., 1995).  Indeed, despite the shared diagnoses of clients in our study, 
GRIP therapists worked with these individuals on a range of issues such as intimate 
relationships and interpersonal struggles, depression, anxiety, anger management, substance 
abuse, physical fitness, and adaptation to illness, to name a few. 
Given this, it will be imperative that GRIP remains a comprehensive and flexible 
treatment program that emphasizes functional recovery and general psychological health in 
addition to illness management.  With respect to the continued evolution of GRIP, this may 
correspond with the addition of new treatment modules (e.g., depression/anxiety), a less 
standardized ordering of treatment phases, and/or greater flexibility in the delivery of 
treatment.  The steps described above represent initial modifications and improvements made 
to enhance the effectiveness and tolerability of GRIP; however, the treatment development 
process is a dynamic one that will continue to unfold as we gather more data from both 
clients and therapists.  It is hoped that our efforts will be successful at keeping young clients 
engaged in treatment, and that the results of our RCT will add to a growing evidence base 
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supporting the efficacy of psychosocial interventions in facilitating symptomatic and 
functional recovery in early psychosis. 
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APPENDIX 
GRIP fidelity rating scale 
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GRIP Session Rating Scale 
 
Therapist: ________     Client initials: _______ Coder:             _________ 
 
Session Number and Date: _______________________ 
 
Instructions: 
 
For the particular session you have observed, please code therapist adherence and 
competence/quality as follows: 
 
Ø Indicate the relevant session block/module that this particular session is from by 
writing in the appropriate code (e.g., 2A; using the criteria below). 
 
Ø Given the relevant session block/module and associated objectives (detailed in 
the coding manual), rate the extent to which both the specific goals and general 
goals for the session were addressed by the therapist on the following scale: 
 
       1           2              3 
Minimal/No      Partial    Comprehensive 
 Coverage    Coverage       Coverage 
 
Ø Indicate whether a perceived protocol deviation seemed appropriate by writing 
“yes” or “no,” or indicate “N/A” if no significant deviation occurred. 
 
Ø Provide an overall quality rating for each session, reflecting how well you believe 
the therapist implemented the prescribed techniques, on the following scale: 
 
   1   2   3   4   5 
Poor                Fair          Good       Very good   Excellent 
 
 
Ratings for this session: 
 
Session Block/Module: _____ 
 
 Specific Goal(s):    _________ 
 
 General Goals:    _________ 
 
 Appropriate Deviation?    _________ 
 
 Overall Quality:     _________ 
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Phase-Specific Goals 
 
Phase One: Engagement and Wellness-Management 
 
· 1A: Sessions 1-2 
o Engage the client in treatment 
o Conduct an initial clinical/psychosocial assessment and elicit client’s narrative about his/her 
illness 
· 1B: Sessions 3-4        
o Provide psychoeducation focused on psychosis and medication    
· 1C: Sessions 5-6     
o Identify therapy goals 
· 1D: Sessions 7-8 
o Develop medication adherence strategies (e.g., using motivational interviewing and/or 
behavioral tailoring) 
· 1E: Sessions 9-10 
o Develop a relapse prevention plan (e.g., identifying warning signs, triggers, and coping 
strategies) 
 
Phase Two: Substance Use 
 
· 2A: Sessions 11-12 
o Provide psychoeducation on the negative consequences of drug and alcohol use 
o Assess current substance use 
· 2B: Sessions 13-20 (if applicable): Part 1 
o Conduct a functional analysis of substance use and instill motivation to reduce use (e.g., 
payoff matrix, motivational interviewing) 
· 2C: Sessions 13-20 (if applicable): Part 2 
o Teach healthy alternatives to drugs/alcohol, teach skills for reducing vulnerability to use 
substances, and develop a substance use relapse prevention plan 
 
Phase Three: Persistent Symptoms 
 
· 3A: Initial assessment 
o Assess the presence/frequency/severity of current positive and negative symptoms 
· 3B: Delusions Module (if applicable) 
o Reduce the conviction in and distress associated with delusions (e.g., increase cognitive 
flexibility, behavioral experiments, reality-testing) 
· 3C: Auditory Hallucinations Module (if applicable) 
o Enhance coping strategies and decrease distress associated with auditory hallucinations (e.g., 
practice new coping strategies, identify antecedents, modify beliefs) 
· 3D: Negative Symptoms Module (if applicable) 
o Reduce consequences of negative symptoms (e.g., inactivity; using behavioral and/or 
cognitive techniques) 
  
Phase Four: Functional Recovery 
 
· 4A: Initial assessment 
o Assess current functional deficits and self-concept 
· 4B: Social Skills Module (if applicable) 
o Build relevant social skills through social skills training 
· 4C: Social Support, Recreation, Role Functioning Module (if applicable) 
o Increase social support (e.g., new opportunities to meet people) 
o Increase pursuit of recreational activities (e.g., activity scheduling) 
o Strengthen role functioning (e.g., connect client with services) 
· 4D: Self-Esteem and Stigma Module (if applicable) 
o Improve self-esteem (e.g., monitor positive qualities) and address stigma concerns  
 
General Goals 
 
Check-in regularly about: goal pursuit and achievement; homework; indigenous supporter (if applicable) 
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Table 1 
 
Characteristics of selected comprehensive (i.e., multi-element) treatment programs for early psychosis 
Note.  a All programs initially prescribe low doses of atypical antipsychotic medication as first- line pharmacological treatment.  b CBT 
= cognitive-behavioral therapy.  c Most programs adhere to an assertive case management model, in which a case manager coordinates 
all treatment for the client, serves as primary contact for the program, and may also assist with vocational and/or housing needs. 
 
Program 
Intake 
age 
range 
In- and 
outpatient 
services? 
Atypical 
anti-
psychotic 
treatmenta 
Individual 
CBT 
and 
supportive 
therapyb 
Group 
therapy 
Family 
therapy 
Case 
mgmtc 
Community 
outreach/ 
early 
detection 
efforts 
Early Psychosis Prevention and 
Intervention Centre (EPPIC)  
Melbourne, Victoria, Australia  15-25 x x X x x x x 
Prevention and Early Intervention 
Program for Psychosis (PEPP) 
London, Ontario, Canada 16-50 x x X x x x x 
Early Psychosis Treatment 
Program (EPTP) 
Calgary, Alberta, Canada 
 
16-45 Outpatient only x X x x x x 
Early Treatment and Identification 
of Psychosis (TIPS) project 
Norway and Denmark 
 
18-65 Outpatient only x ST only  x x x 
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Table 2 
Summary of studies evaluating the effectiveness of specific psychosocial treatments for early psychosis 
 
OUTCOMESi i i 
Study N Interventioni Comparison Groupi i 
Treatment 
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Follow-up 
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Q
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vi
i  Other Outcomes 
RANDOMIZED CONTROLLED TRIALS 
Individual Interventions 
Haddock 
et al., 
1999 
21+ Individual CBT 
Supportive 
counseling 
5 weeks; 
booster 
sessions 
over 4 
months 
= NA = NA  
Lewis et 
al., 2002 309+ Individual CBT 
Supportive 
counseling (SC) 
 
Routine care  
5 weeks; 
booster 
sessions 
over 3 
months 
=  NA NA NA 
Trend for CBT group to 
improve fastest; Auditory 
hallucinations responded 
better to CBT vs. SC 
Jolley et 
al., 2003 
21+ Individual CBT Routine care 
6 months 
(mean=11 
sessions) 
=  NA = NA 
Less time in hospital for 
CBT group 
Power et 
al., 2003 
56** 
Acute 
suicidality 
Individual CBT 
(“LifeSPAN”) at EPPIC 
EPPIC services w/o 
LifeSPAN 
8-10 
sessions; 6 
month 
follow-up 
= = NA + 
LifeSPAN > control for 
helplessness; both groups 
improved on suicidal 
ideation and attempts 
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Wang et 
al., 2003 
251* Individual CBT Routine care (RC) 
2 year 
follow-up 
+ NA + NA 
CBT>RC for insight, 
treatment adherence 
Kavanagh 
et al., 
2004 
25++ 
Motivational 
Interviewing (MI) 
Standard Care (SC) 
7-10 days; 
12 month 
follow-up 
NA NA NA NA 
MI group had significantly 
better substance-use 
outcomes at 6 months than 
SC   
Tarrier et 
al., 2004 
225+ Individual CBT 
Supportive 
counseling (SC) 
 
Routine care (RC) 
18 month 
follow-up of 
Lewis et al., 
2002 
CBT=SC 
 
CBT/SC 
>RC 
NA = NA 
Auditory hallucinations 
responded better to CBT 
vs. SC 
Edwards 
et al., 
2006 
47** 
Individual CBT (CAP) 
at EPPIC  
Psychoeducation 
10 sessions; 
6 month 
follow-up 
= = NA = 
Significant decrease in 
cannabis use in both 
groups, no significant 
group differences in 
cannabis use. 
Tarrier et 
al., 2006 278+ Individual CBT 
Supportive 
counseling (SC) 
 
Routine care (RC) 
18 month 
follow-up of 
Lewis et al., 
2002 
NA NA NA NA 
No beneficial or adverse 
effects of intervention on 
suicide behavior. Higher 
psychotic symptom levels, 
poorer functioning, 
depression and low-self 
esteem associated with a 
higher severity of suicide 
behavior. 
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Family Interventions 
Zhang et 
al., 1994 83* Family therapy Routine Care 18 months 
+  
(in 
patients 
not 
admitted 
to 
hospital) 
NA + 
+ 
(in 
patients 
not 
admitted 
to 
hospital) 
 
Family group spent less 
time in hospital 
Linszen 
et al., 
1996 
76+ 
Behavioral family 
therapy (and individual 
therapy) 
Individual therapy 
only 12 NA NA = NA 
Family therapy associated 
with slightly higher 
relapse rates (nonsig 
differences) among low 
expressed emotion 
families 
Lenior et 
al., 2001 73+ 
Behavioral family 
therapy (and individual 
therapy) 
Individual therapy 
only 
5 year 
follow-up to 
Linszen et 
al., 1996 
NA NA = = 
Family therapy group 
spent less time in 
hospitals; 65% of all 
patients relapsed at least 
once in 5 years. 
Lenior et 
al., 2002 73+ 
Behavioral family 
therapy (and individual 
therapy) 
Individual therapy 
only 
5 year 
follow-up to 
Linszen et 
al., 1996 
NA NA = NA 
No differential effect of 
family therapy on 
expressed emotion 
Leavey et 
al., 2004 106** 
Carer-focused 
psychoeducation 
Treatment as usual 
(TAU) 
7 sessions; 9 
month 
follow-up 
NA NA = NA 
No significant differences 
in satisfaction with 
services or perceived 
severity of illness for 
carers 
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QUASI-EXPERIMENTAL TRIALS 
Individual Interventions 
Jackson 
et al., 
1998 
80** 
Individual CBT 
(“COPE) at EPPIC 
EPPIC services w/o 
COPE (refusers) 
 
EPPIC inpatient care 
only (control) 
12 months 
(median=19 
sessions) 
= 
COPE
> 
control 
= COPE> control 
COPE > refusers and 
control for adaptation to 
illness; COPE>control for 
insight/attitudes toward 
treatment 
Jackson 
et al., 
2001 
51** 
Individual CBT 
(“COPE) at EPPIC 
EPPIC services w/o 
COPE (refusers) 
 
EPPIC inpatient care 
only (control) 
12 month 
follow-up of 
Jackson et 
al., 1998 
= = = = 
COPE > refusers for 
adaptation to illness 
Jackson 
et al., 
2005 
91** 
Individual CBT 
(“COPE) at EPPIC 
EPPIC services w/o 
COPE (NO-COPE) 
4 year 
follow-up of 
Jackson et 
al., 1998 
= = = = 
Over 4 year follow-up, 
50% of patients in COPE 
group and 44% of patients 
in NO-COPE group were 
rehospitalized. 
Family Interventions 
Lehtinen, 
1993 81+ 
Family-oriented 
treatment 
Individual-oriented 
treatment (historical 
control) 
 
 
5 year 
follow-up + NA + NA 
Family group spent less 
time in hospital 
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Group Interventions 
Albiston 
et al., 
1998 
95** EPPIC group program 
EPPIC services w/o 
groups 
Multiple 
groups/wk; 
6 month 
follow-up 
NA = NA = 
Note: At baseline, group 
participants had lower 
premorbid functioning and 
trend toward more 
negative symptoms  
Miller & 
Mason, 
2001 
77* Group therapy Individual therapy 
1x/week for 
2 years NA NA NA NA 
Group therapy associated 
with better treatment 
adherence (i.e. fewer 
dropouts) 
 
 
SINGLE GROUP TRIALS 
Lecomte 
et al., 
2003 
5* Group CBT NA 
2x/week for 
3 months NA NA NA NA 
Group therapy associated 
with high treatment 
satisfaction and decrease 
in psychotic symptoms  
 
Note.  * = Nonaffective FE psychosis, ** = Nonaffective and affective FE psychosis, + = Nonaffective early psychosis, ++ = 
Nonaffective and affective early psychosis (where nonaffective psychoses were schizophrenia spectrum disorders, and affective 
psychoses were mood disorders with psychotic features.)  
 
i Elements of the EPPIC intervention are shown in Table 1. Psychosocial treatments were always adjunctive to pharmacological 
treatment unless otherwise noted. 
ii Routine care was primarily medication management. 
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iii For “Outcomes”:  “+” indicates that patients in the intervention program did significantly better than the comparison group(s) in 
studies with an experimental or quasi-experimental design or that there was significant improvement over time in studies with a 
single-group design. “=” denotes no significant difference between the intervention and comparison groups in studies with an 
experimental or quasi-experimental design or that there was no change over time in studies with a single-group design. 
iv Measures were the Brief Psychiatric Rating Scale, Psychotic Symptom Rating Scales, Positive and Negative Syndrome Scale, and 
chart notes. 
v Measure was the Scale for the Assessment of Negative Symptoms 
vi Relapse was variably defined as change in patient management (per medical records), hospital admission, and Score on the Life 
Chart Schedule. 
vii Measures were the Quality of Life Scale, Global Assessment of Functioning Scale score, and Life Chart Schedule. 
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Table 3 
Characteristics of recovery from psychosis 
Elements of recovery 
Illness-management (e.g., medication adherence, coping skills, relapse prevention) 
Optimism and sense of control over illness 
Functional recovery and “moving beyond” illness 
Facilitators of recovery 
Fixed (prior to therapy) Malleable 
Good premorbid functioning Medication adherence 
Female gender Increased knowledge of illness 
Later age of onset Improved coping skills 
Higher socioeconomic status Relapse prevention plan 
Shorter duration of untreated 
psychosis 
No substance use 
Better initial response to medication Management of residual symptoms 
 Hope, optimism, and high self-esteem 
 Pursuit of relevant goals 
 Improved social/occupational functioning 
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Table 4 
Overview of the Graduated Recovery Intervention Program (GRIP) 
Treatment phase 
(# sessions) 
 
Goals Strategies 
Engagement · Introduce client to 
treatment 
· Elicit client’s personal 
experience with illness 
· Identify indigenous 
supporter 
Psychoeducation · Handouts on psychosis 
and medication 
· Introduce stress-
vulnerability model 
· Integrate client’s 
personal experience 
Goal setting · Identify short- and long-
term goals 
· Use scaling techniques 
Improve medication 
adherence 
· Evaluate attitudes 
toward medication 
· Behavioral tailoring and 
motivational techniques 
Engagement and 
wellness-management 
(10) 
Develop relapse prevention 
plan 
· Identify warning signs, 
triggers, and coping 
strategies 
Psychoeducation · Handout on effects of 
substance use 
· Integrate client’s 
personal experience 
Increase motivation to 
decrease substance use 
· Motivational 
interviewing 
Substance use 
(2-10) 
Develop substance use 
relapse prevention plan 
· Identify healthy 
alternatives to substance 
use 
· Identify high-risk 
situations and coping 
skills/strategies 
Residual symptoms 
(flexible; up to 12) 
Reduce conviction in 
delusional beliefs 
· Increase cognitive 
flexibility 
· Behavioral experiments 
· Reality-testing 
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Reduce distress associated 
with auditory hallucinations 
· Identify antecedents and 
consequences of voices 
· Identify and practice 
adaptive coping 
strategies 
· Interpersonalize 
voices/modify beliefs 
· Behavioral experiments 
Reduce effects of negative 
symptoms 
· Activity 
scheduling/behavioral 
activation 
Improve social skills and 
social support 
· Social skills training 
· Problem-solving 
· Discussion of 
relationship issues 
Strengthen role-functioning 
(i.e., school/work 
performance) 
· Problem-solving 
· Break down larger goals 
· Connect clients to 
services (e.g., supported 
employment) 
Increase leisure activity · Activity scheduling 
Functional recovery 
(flexible; up to 24) 
Improve self-esteem · Encourage pursuit of 
goals 
· Address stigma 
· Foster hope and 
optimism 
· Monitor positive 
qualities 
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  Table 5 
Baseline characteristics of sample for GRIP open trial (N = 10) 
Gender (n) 
 Males      7 
 Females     3 
 Ethnicity (n) 
 Caucasian     6 
 African-American    2 
 Other      2 
 Age (years)a     25 ± 5 
 Education (n) 
 Did not complete high school   1 
 High school diploma/GED   1 
 Some college      7 
 College degree    0 
 Advanced degree (e.g., Ph.D.)  1 
 Marital status (n) 
 Never married     9 
 Married     1 
 Primary diagnosis (n) 
 Schizophrenia     5 
 Schizoaffective    1 
 Schizophreniform    4      
 Comorbid diagnoses (n) 
 Substance abuse    3 
 Anxiety disorder    1 
 Major depression    1 
 Duration of untreated illness (months)b,c  13 
 Duration of untreated psychosis (months)b,d 3 
 Number of previous hospitalizations (n) 
 None      5 
 One      3 
 Two      2 
 Medication usage (n) 
 Atypical antipsychotic    10     
 Mood stabilizer    1 
 Antidepressant     3 
 Anxiolytic (i.e., benzodiazepine)  1 
 Other      3 
a M ± SD.  b Median.  c Duration of untreated illness = approximate length of time between 
patient-reported onset of first prodromal symptoms and initiation of antipsychotic 
medication.  d Duration of untreated psychosis = approximate length of time between patient-
reported onset of active psychosis (i.e., DSM-IV schizophrenia criterion “A”) and initiation 
of antipsychotic medication.
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Table 6 
 
Summary of revisions made to the GRIP manual 
 
Introduction 
 
· Added sections on: 
o Aims of GRIP and focus on goals 
o Confidentiality 
o Liaising with treatment team 
o Working with families 
o Assessment (including recommended instruments) 
o Suicide assessment and prevention in first episode psychosis 
(FEP) 
o Termination issues in FEP 
· Enhanced section on developing alliance in FEP 
· Clarified: rationale for 4-phase approach; target population; recommended 
flow of treatment and need to prioritize pressing concerns; ways of 
incorporating homework, indigenous supporters, and goals on an ongoing 
basis 
 
Phase One 
 
· Added: 
o Section on initial clinical/psychosocial assessment 
o References (web sites, fact sheets, videos) for psychoeducation, 
including resources for family/friends 
o Further guidance regarding questions of diagnosis, prognosis, 
medication 
· Clarified that GRIP can be presented as “up to 36 sessions” if clients are 
not keen on idea of 9 months of treatment at beginning 
· Expanded on motivational interviewing information 
 
Phase Two 
 
· Added section on: dealing with ongoing substance use following end of 
the phase and developing realistic expectations (i.e., harm reduction vs. 
abstinence) 
· Provided additional guidance on addressing denial and/or minimization of 
use 
· Emphasized that substance use will need to be addressed on an ongoing 
basis in many clients 
· Expanded on psychoeducational material (including references for clients 
explaining why substances are harmful) and motivational interviewing 
information 
· Highlighted key drugs in FEP (i.e., cannabis and alcohol), and provided 
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sample dialogue discussing these drugs 
· Clarified nature of optional sessions (i.e., need all eight for current abuse) 
 
Phase Three 
 
· Added: assessment section; overview/outline of problem areas with 
recommended techniques; general guidelines for working with multiple 
problem areas and when to move on 
· Expanded negative symptoms section to include: more background 
information; new technique: cognitive restructuring of self-defeating 
beliefs; tips for working with negative symptoms in early psychosis 
 
Phase Four 
 
· Added: assessment section; overview/outline of problem areas with 
recommended techniques; general guidelines for working with multiple 
problem areas and when to move on 
· Expanded on social skills training (SST) module by adding: 
o Assessment section 
o General principles of SST 
o Several common skills deficits and steps involved 
o Guidelines for evaluation of SST 
o Reference to revised (2004) Bellack book 
· Expanded on social support module by providing guidance on 
strengthening existing relationships/increasing closeness 
· Provided overview of supported employment programs in role functioning 
module 
 
General/miscellaneous 
 
· Added: 
o Troubleshooting section 
o Glossary of core techniques 
· Expanded on instructional material for variety of techniques 
· Highlighted challenges of working with FE population, including high 
suicide risk and need to assess 
· Provided additional guidance on prioritizing pressing client concerns and 
addressing ongoing problems (e.g., substance use, medication non-
adherence) 
· Re-designed some worksheets/handouts to make more user-friendly 
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Table 7 
 Baseline differences on selected variables between treatment completers and non-completers 
 Completers (n = 6) Non-completers (n = 4) 
Age 
(years) 
29 22 
Duration of untreated illness 
(months) 
12 18.5 
Duration of untreated 
psychosis (months) 
1 8.5 
SFS - social engagement 12.5 8.5 
SFS - prosocial 13.5 10.5 
SFS - total 121 112.5 
PANSS - total 56 59 
MSPSS* 43 31 
Note.  All values reported are median values.  Visual inspection of baseline data was 
conducted to identify domains with potentially meaningful between-group differences.  
“Completers” attended at least 12 sessions of therapy; “Non-completers” attended fewer than 
12 sessions of therapy.  Duration of untreated illness = approximate length of time between 
patient-reported onset of first prodromal symptoms and initiation of antipsychotic 
medication.  Duration of untreated psychosis = approximate length of time between patient-
reported onset of active psychosis (i.e., DSM-IV schizophrenia criterion “A”) and initiation 
of antipsychotic medication. 
 
SFS = Social Functioning Scale.  PANSS = Positive and Negative Syndrome Scale. 
MSPSS = Multidimensional Scale of Perceived Social Support. 
 
* p < .05  
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Table 8 
Means (S.D.) for all continuous outcome variables in GRIP open trial 
SFS 
total 
PANSS 
positive 
PANSS 
negative 
PANSS 
general 
PANSS 
total MSPSS CDSS 
 
BEMIB 
  
B P B P B P B P B P B P B P B P 
All 
(N = 9) 
116.4 
(21.1) 
119.8 
(23.4) 
13.6 
(3.1) 
11.1 
(4.0) 
15.2 
(5.2) 
14.6 
(6.0) 
28.3 
(6.0) 
26.7 
(6.9) 
57.1 
(10.9) 
52.3 
(14.1) 
40.1 
(7.8) 
39.0 
(12.6) 
3.8 
(4.4) 
2.4 
(1.7) 
30.9 
(4.4) 
30.6 
(3.9) 
Completers 
(n = 6) 
115.9 
(24.3) 
126.9 
(21.4) 
13.0 
(3.3) 
10.0 
(3.2) 
15.7 
(6.1) 
13.2 
(4.6) 
29.0 
(7.4) 
25.2 
(6.7) 
57.7 
(12.8) 
48.3 
(10.1) 
43.3 
(7.2) 
42.7 
(12.0) 
3.5 
(5.3) 
2.2 
(1.8) 
30.7 
(5.0) 
32.0 
(4.0) 
Non-
completers 
(n = 3) 
117.5 
(17.4) 
105.6 
(24.1) 
14.7 
(3.1) 
13.3 
(5.1) 
14.3 
(3.5) 
17.3 
(8.5) 
27.0 
(2.0) 
29.7 
(7.6) 
56.0 
(7.9) 
60.3 
(19.9) 
33.7 
(4.7) 
31.7 
(12.4) 
4.3 
(2.5) 
3.0 
(1.7) 
31.3 
(4.0) 
27.7 
(1.2) 
Note. B = baseline; P = post-test.  “Completers” attended at least 12 sessions of therapy; “Non-completers” attended fewer than 12 
sessions of therapy. 
 
SFS = Social Functioning Scale.  PANSS = Positive and Negative Syndrome Scale.  MSPSS = Multidimensional Scale of Perceived 
Social Support.  CDSS = Calgary Depression Scale for Schizophrenia.  BEMIB = Brief Evaluation of Medication Influences and 
Beliefs. 
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Table 9 
Within-group effect sizes for continuous outcome variables in GRIP open trial 
 SFS 
total 
PANSS 
positive 
PANSS 
negative 
PANSS 
general 
PANSS 
total 
MSPSS CDSS BEMIB 
 
All 
(N = 9) 
 
.16 
(.10) 
.78 
(.66) 
.13 
(.12) 
.28 
(.26) 
.44 
(.38) 
-.14 
(-.10) 
.31 
(.38) 
-.10 
(-.08) 
Completers 
(n = 6) 
 
.45 
(.48) 
.91 
(.92) 
.41 
(.46) 
.52 
(.54) 
.73 
(.80) 
-.10 
(-.07) 
.25 
(.31) 
.27 
(.28) 
Non-
completers 
(n = 3) 
 
-.70 
(-.57) 
.44 
(.26) 
-.85 
(-.03) 
-1.34 
(-.34) 
-.55 
(-.02) 
-.42 
(-.22) 
.53 
(.61) 
-.91 
(-.75) 
Note. A positive effect size indicates improvement, and a negative effect size indicates 
deterioration.  Values reported represent conventional estimates of Cohen’s d and corrected 
estimates of Cohen’s d (in parentheses; using methods recommended by Dunlap et al., 1996).  
“Completers” attended at least 12 sessions of therapy; “Non-completers” attended fewer than 
12 sessions of therapy. 
 
SFS = Social Functioning Scale.  PANSS = Positive and Negative Syndrome Scale. 
MSPSS = Multidimensional Scale of Perceived Social Support.  CDSS = Calgary Depression 
Scale for Schizophrenia.  BEMIB = Brief Evaluation of Medication Influences and Beliefs. 
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Table 10 
Clinically significant change on the PANSS 
 Completers (n) Non-completers (n) 
 20% reduction 50% reduction 20% reduction 50% reduction 
Positive symptoms 3 1 1 0 
Negative symptoms 3 1 0 0 
General symptoms 2 0 0 0 
Total score 2 0 0 0 
Note.  Per convention, a 20% decrease on a PANSS subscale is defined as “clinically 
significant change” (e.g., Cather et al., 2005).  “Completers” attended at least 12 sessions of 
therapy; “Non-completers” attended fewer than 12 sessions of therapy. 
 
PANSS = Positive and Negative Syndrome Scale. 
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Table 11 
Feedback on GRIP from participants and therapists 
 Responsea 
                 
 
Item 
 “1” 
(% of respondents) 
 “2” 
(% of respondents) 
 “3” 
(% of respondents) 
 
Participant ratingsb 
 
 completers non-completers completers 
non-
completers completers 
non-
completers 
How useful was 
GRIP to you? 
0 67 17 33 83 0 
How would you 
rate quality and 
service in GRIP? 
0 67 17 33 83 0 
Was the program 
respectful to you? 
0 0 0 100 100 0 
How much did 
GRIP help with 
your symptoms? 
0 67 67 33 33 0 
How much did 
GRIP help with 
your recovery? 
0 67 33 33 67 0 
Did GRIP cover 
the right amount of 
information? 
0 33 0 0 100 67 
Were the materials 
in GRIP easy to 
understand? 
0 0 33 100 67 0 
Overall, did GRIP 
meet your therapy 
needs? 
 
0 33 33 67 67 0 
Therapist ratingsc 
 
Overall, how 
helpful was the 
GRIP manual? 
0 56 44 
Did the GRIP 
educational 
handouts cover the 
right amount of 
information? 
11 0 89 
How much did the 33 67 0 
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program help you 
support your 
clients in 
managing their 
psychiatric 
symptoms? 
How much did the 
program help you 
support your 
clients in moving 
forward with their 
recovery? 
33 56 11 
How much would 
you recommend 
the GRIP manual 
and materials to 
another 
practitioner? 
 
0 22 78 
Note. a All items were rated from 1-3, with 1 indicating most negative response (e.g., “not at 
all helpful,” “poor service,” “difficult to understand”) and 3 indicating most positive response 
(e.g., “very helpful,” “excellent service,” “very easy to understand”). 
b Participant ratings are categorized by treatment completion status.  “Completers” attended 
at least 12 sessions of therapy (n = 6); “Non-completers” attended fewer than 12 sessions of 
therapy (n = 3). 
c All five therapists completed a feedback form for each client who completed a post-
treatment assessment (N = 9); thus, results shown are percentages of responses from 9 
feedback forms. 
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